

---

1977 - 2010




**Fondazione Angelo Bianchi Bonomi**

Più di trent'anni di attività  
More than thirty years of activity

**Relazione 2006 - 2010**  
Report 2006 - 2010

---



**Fondatore**  
Angelo Bianchi Bonomi

**Consiglio di Amministrazione:**

Ambrogio Bianchi Bonomi (Presidente Onorario)  
Barbara Bianchi Bonomi (Presidente)  
Raffaella Brambilla  
Pier Mannuccio Mannucci  
Carlangelo Menni  
Ileana Zucchi

**Revisori:**

Paolo Francesco Lazzati  
Anna Strazzera  
Giuseppe Ugo



## Fondazione Angelo Bianchi Bonomi

**UniCredit Private Banking**  
**Milano**  
Filiale 07570 Armorari  
CIN L ABI 02008 CAB 09423  
C/C 000001770966  
IBAN: IT088L0200809423000001770966  
BIC SWIFT: UNCRITM169Y

**Banco Popolare**  
**Verona e Novara**  
Sede Milano Largo Cairoli, 2  
CIN V ABI 05188 CAB 01600  
C/C 000000166415  
IBAN: IT82V0518801600000000166415

Per lo studio e la ricerca nel campo  
dell'emofilia, della trombosi e delle  
malattie emorragiche.

Ente riconosciuto D.P.R. n. 1189 del 22.6.1977.  
Membro associato della World Federation of  
Hemophilia

Piazza Castello, 2 - 20121 Milano - Italia  
Tel. ++39/02/86450532  
Fax ++39/02/875444  
[www.fondazionebianchibonomi.it](http://www.fondazionebianchibonomi.it)

Medici e ricercatori del  
Centro Angelo Bianchi Bonomi  
con Barbara Bianchi Bonomi,  
Presidente della Fondazione,  
Pier Mannuccio Mannucci  
Direttore Scientifico della Fondazione  
e Ambrogio Bianchi Bonomi  
Presidente onorario



È per me motivo di orgoglio presentare questo rapporto relativo agli ultimi 4 anni di attività (2006-2010) della Fondazione Angelo Bianchi Bonomi e del Centro Emofilia e Trombosi che porta lo stesso nome. I conseguimenti scientifici del Centro, il reclutamento di giovani ricercatori e il potenziamento dell'attività clinica (da cui dipende la ricerca) sono sempre sostenuti in maniera determinante dalla Fondazione, e dal Consiglio di Amministrazione. Angelo Bianchi Bonomi, deceduto nell'agosto 1971, non ha visto realizzarsi i suoi intendimenti, ma la sua memoria viene onorata dalla notorietà, fama e prestigio internazionale di cui godono la Fondazione ed il Centro a lui intitolati e operanti da quasi 40 anni.

Pier Mannuccio Mannucci

*It is for me a pleasure to present to the scientific community this report on the past few years of activity (2006-2010) of the Angelo Bianchi Bonomi Foundation and of the Hemophilia and Thrombosis Center. The scientific activities of the Center, the recruitment of young investigators and the potentiation of the clinical facilities of the Center (from which research activities stem) are being strongly supported by the Foundation, and Board of Trustees. Angelo Bianchi Bonomi, who passed away on August 1971, has not witnessed the realization of his projects. His memory is honoured by the recognition achieved along nearly 40 years of activity by the Foundation and Center dedicated to him.*

Pier Mannuccio Mannucci

La Fondazione nata nel 1971 in memoria di nostro padre continua la sua opera in aiuto alla ricerca scientifica sostenendo il Centro Emofilia e Trombosi Angelo Bianchi Bonomi nel suo campo di attività, con la creazione del Centro Universitario e Ospedaliero Angelo Bianchi Bonomi e con il finanziamento di due cattedre universitarie di Medicina Interna. I riconoscimenti ottenuti dal Centro sia in campo nazionale che internazionale testimoniano gli obiettivi raggiunti dall'instancabile lavoro di quanti collaborano con la Fondazione. A tutte le persone che con la loro dedizione, professionalità e competenza contribuiscono da oltre 40 anni al prestigio della Fondazione vada il nostro più sincero e profondo ringraziamento.

Carla Bianchi Bonomi  
Ambrogio Bianchi Bonomi

*The Foundation, created in 1971 in memory of our father, continues to support research at the Hemophilia and Thrombosis Center Angelo Bianchi Bonomi, recently through the University recognition of the Center and the endowment of two University Chairs of Internal Medicine. The national and international achievements of the Center demonstrate that important goals were achieved with the tireless work of all the collaborators and supporters of the Foundation. We warmly wish to thank all those people who over more than 40 years are contributing to the prestige of the Foundation with their qualified, professional and devoted work.*

Carla Bianchi Bonomi  
Ambrogio Bianchi Bonomi

## Una storia di impegno e ricerca

Nel 1971 la famiglia Bianchi Bonomi decise di costituire la Fondazione Angelo Bianchi Bonomi allo scopo di creare un ente di utilità sociale per aiutare la ricerca scientifica sull'emofilia, le malattie ereditarie della coagulazione del sangue e la trombosi.

La Fondazione venne dotata di un patrimonio immobiliare ed ottenne personalità giuridica in data 22 giugno 1977 con DPR n. 1189.

La principale attività della Fondazione consiste nel sostenere il Centro Emofilia e Trombosi Angelo Bianchi Bonomi dell'Ospedale Maggiore (ora Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico) e dell'Università degli Studi di Milano.

Tale attività si esplica nell'erogazione di borse di studio per giovani ricercatori italiani e stranieri, strutturazione di laboratori ed ambulatori e dotazione di apparecchiature scientifiche.

La prima tappa che la Fondazione volle raggiungere fu la creazione a Milano di un Centro Medico dove medici e ricercatori potessero svolgere la loro attività scientifica e clinica nel settore specifico delle malattie ereditarie della coagulazione.

La Fondazione ha quindi provveduto a strutturare presso l'Ospedale Maggiore di Milano una serie di laboratori dotati dei necessari arredi ed attrezzature scientifiche, che vennero donati all'Ospedale stesso.

A sua volta, l'Ospedale intitolò il Centro ad Angelo Bianchi Bonomi. In seguito è stato creato il Centro Universitario con lo stesso nome.

La Fondazione ha anche sponsorizzato due Cattedre di Professore di Medicina Interna presso l'Università degli Studi di Milano. La Fondazione ha inoltre indirizzato i suoi programmi verso l'erogazione di borse di studio che consentissero a giovani medici e ricercatori, italiani o stranieri, di dedicarsi ad attività di ricerca presso il Centro.

A tutto il 2010 la Fondazione Angelo Bianchi Bonomi ha assegnato un grande numero di borse di studio, 205 a medici e ricercatori italiani e stranieri provenienti da varie parti del mondo (Argentina, Cina, Colombia, India, Inghilterra, Iran, Tailandia, Turchia, Slovenia, Germania, Olanda). Sono stati inoltre assegnati 93 premi per fini di studio.

Dal 1992 al 2002 ha istituito un premio internazionale su base annuale per giovani ricercatori per le migliori ricerche scientifiche nel campo delle malattie congenite della coagulazione.

Dall'anno 2010 la Fondazione sponsorizza uno studio internazionale randomizzato (SIPPET) che si svolge in 78 centri di 19 paesi dei cinque continenti.

Lo scopo dello studio è di stabilire se vi è una diversa incidenza di sviluppo di inibitori del fattore VIII in bambini emofilici mai precedentemente trattati con fattore VIII di origine ricombinante o plasmatico.

La possibilità che la Fondazione ha, ed ha avuto, di sostenere il Centro Angelo Bianchi Bonomi è dovuta sia a mezzi finanziari propri che al generoso contributo di numerose società, enti e persone alle quali va tutta la nostra riconoscenza.

Citiamo, in particolare, e ringraziamo per gli importanti e continuativi contributi elargiti alla Fondazione: la Fondazione Cariplo, Rolo Banca 1473 (che tramite la Fondazione, ha provveduto a donare al Centro numerose apparecchiature scientifiche), UniCredit Private Banking e Banca Aletti.

P.M. Mannucci

*Direttore Scientifico Fondazione Angelo Bianchi Bonomi  
Professore di Medicina Interna,  
Direttore Scientifico, IRCCS Fondazione Cà Granda  
Ospedale Maggiore Policlinico*

## *A story of diligence and research*

In 1971 the Bianchi Bonomi family created the Angelo Bianchi Bonomi Foundation, an institution meant to support scientific research in a medical field of great importance: hemophilia, other congenital coagulation disorders and thrombosis.

The Foundation was endowed with real estates which provide a funding basis, and was given legal status on June 22, 1977 (D.P.R. 1189).

The Foundation supports mainly the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center of the Maggiore Hospital and of the Milano University, through the award of fellowships, scientific equipment and construction of new laboratories.

The first accomplishment of the Foundation was the creation of a research center where clinicians and scientists work together in the field of coagulation disorders. To this end the Foundation has built a laboratory at the Maggiore Hospital in via Pace (Milan), providing all the necessary equipment that was donated to the Hospital. In turn, the Hospital has dedicated the Hemophilia and Thrombosis Center to the memory of Angelo Bianchi Bonomi.

Subsequently the Center was recognized with the same name by the University of Milan. The Foundation has endowed the University of Milan with two Chairs of Associate Professor of Internal Medicine.

The Foundation has continued to address its programs towards the support of the scientific activity of the Hemophilia and Thrombosis Center.

So far the Foundation has awarded a number of research fellowships that have allowed 205 young Italian and foreigner investigators from other countries (Argentina, China, Colombia, India, Iran, The Netherlands, Thailand, Turkey, Slovenia, Germany, United Kingdom) to work at the Center. 93 research Prizes have also been assigned.

From 1992 until 2002 the Foundation has awarded on annual basis two International Prizes for young investigators for the best scientific papers of the year on congenital coagulation disorders.

Starting in 2010 the Foundation is sponsoring a randomized international trial involving 78 sites in 19 countries in all the continents.

The SIPPET study has the goal to establish whether or not plasma-derived and recombinant factor VIII products cause a different incidence of factor VIII inhibitors in previously untreated hemophilic boys.

The support given to the Angelo Bianchi Bonomi Center by the Foundation is based not only on its own sources of funds, it is complemented by the generous contributions of several institutions and individuals that are acknowledged: specially, for important continued support to the Foundation, Fondazione Cariplo and Rolo Banca 1473 that, through the Foundation, has donated to the Center several scientific instruments, UniCredit Private Banking and Banca Aletti

PM. Mannucci

*Scientific Director Fondazione Angelo Bianchi Bonomi  
Professor of Internal Medicine,  
Scientific Director, IRCCS Fondation Cà Granda  
Ospedale Maggiore Policlinico*

## Centro Emofilia e Trombosi Angelo Bianchi Bonomi

Il Centro Emofilia e Trombosi Angelo Bianchi Bonomi, riconosciuto dall'Ospedale Policlinico e dall'Università degli Studi di Milano è la principale attività della Fondazione Bianchi Bonomi. Tale attività si esplica nell'erogazione di borse e premi di studio per giovani ricercatori italiani e stranieri, strutturazione di laboratori ed ambulatori e dotazione di apparecchiature scientifiche.

Con i contributi della Fondazione, dell'Ospedale Maggiore Policlinico, dell'Università di Milano e di vari enti scientifici italiani ed esteri (National Institutes of Health USA, European Union Biomed, Fondazione Italo Monzino, Fondazione Luigi Villa), il Centro ha ottenuto significativi risultati assistenziali e scientifici nel campo delle malattie della coagulazione del sangue, sia quelle emorragiche da difetto di coagulazione che quelle trombotiche da eccesso di coagulazione. Centro di Riferimento della Regione Lombardia, Centro collaboratore dell'Organizzazione Mondiale della Sanità di Ginevra e della Federazione Mondiale dell'Emofilia di Montreal, assiste regolarmente più di 3000 pazienti con malattie emorragiche e trombotiche, con diagnosi e terapia in regime ambulatoriale, di day-hospital e di ricovero ospedaliero.

Sono più di 1000 le pubblicazioni del Centro sui maggiori giornali scientifici internazionali di medicina interna e di ematologia, fra cui Lancet, New England Journal of Medicine, Annals of Internal Medicine e Blood.

Il Centro Angelo Bianchi Bonomi ha ricevuto contributi finanziari dai National Institutes of Health per ricerche sulla desmopressina; dall'Unione Europea (Biomed) per lo studio delle più idonee terapie nella malattia di von Willebrand o angioemofilia e per l'esecuzione della diagnosi genetica nei pazienti con questi difetti; dalla Fondazione Cariplò e dalla Fondazione Italo Monzino

per lo studio delle malattie rare della coagulazione; nonché dal Ministero della Salute, nell'ambito della ricerca corrente e della ricerca finalizzata dell'Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Maggiore Policlinico. Il Centro Angelo Bianchi Bonomi si è affermato fra i primi in Italia e nel mondo in questo settore della medicina clinica e di laboratorio.

### **Direttore:**

Flora Peyvandi, Professore associato di Medicina Interna

### **CENTRO UNIVERSITARIO DI RICERCA**

In data 21 dicembre 2001 il Rettore dell'Università degli Studi di Milano decreta:

Presso l'Università degli Studi di Milano - Facoltà di Medicina e Chirurgia è istituito, con decorrenza dal 1° Gennaio 2002, il centro Università di ricerca convenzionato denominato Angelo Bianchi Bonomi, del Dipartimento di medicina Interna.

### **Direttore:**

Professore Flora Peyvandi



Centro Emofilia e Trombosi Angelo Bianchi Bonomi,  
Via Pace, 15 - 20122 Milano - Italia  
Tel. +39.02.55035421 Fax +39.02.5516093  
[www.bianchibonomi-htcenter.it](http://www.bianchibonomi-htcenter.it)

## Hemophilia and Thrombosis Center Angelo Bianchi Bonomi

The Bianchi Bonomi Foundation's main work is with the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, at the University of Milan Polyclinic Hospital. The work includes providing scholarships and academic awards to young researchers (Italian and foreign), building laboratories and clinics, and donating scientific equipment.

With contributions from the Foundation, the Maggiore Polyclinic Hospital, the University of Milan, as well as various Italian and foreign scientific entities (including the National Institutes of Health (USA), Biomed (EU), the Italo Monzino Foundation, and the Luigi Villa Foundation), the Center has achieved significant results in the care and of science of blood coagulation disorders, including those that are hemorrhagic (insufficient coagulation) and thrombotic (excessive coagulation). The Lombardy based specialist referral center, partnered with the World Health Organization in Geneva and the World Federation of Hemophilia in Montreal, regularly provides diagnosis and therapy to more than 3,000 patients with hemorrhagic and thrombotic disorders on an outpatient as well as inpatient basis.

The Center has published over 1000 papers in leading international science journals of internal medicine and hematology, including The Lancet, The New England Journal of Medicine, Annals of Internal Medicine, and Blood Journal.

The Angelo Bianchi Bonomi Center has received research funding from the following entities: the National Institutes of Health for desmopressin research; the European Union (Biomed) to study the most suitable therapies for von Willebrand factors or angio hemophilia; from the Italo Monzino Foundation to study rare coagulation disorders; with the most significant source of funding from the Ministry of Health for ongoing and

directed research at the Maggiore Polyclinic Research Hospital. The Center Angelo Bianchi Bonomi has established itself as a leader in Italy and worldwide in the field of clinical medicine and laboratory research.

### Director:

Flora Peyvandi, associate professor  
of Internal Medicine

## UNIVERSITY RESEARCH CENTER

21 December 2001, the Rector of the University of Milan decreed:

The University Research Center, Angelo Bianchi Bonomi is hereby established at the University of Milan, Medicine and Surgery Faculty, Department of Internal Medicine, starting 1 January 2002.

### Director:

Professor Flora Peyvandi



Angelo Bianchi Bonomi Hemophilia and Thrombosis Center  
Via Pace, 15 - 20122 Milan - Italy  
Tel. +39.02.55035421 Fax +39.02.5516093  
[www.bianchibonomi-htcenter.it](http://www.bianchibonomi-htcenter.it)

## Attività e riconoscimenti del Centro Emofilia e Trombosi Angelo Bianchi Bonomi

### *Tasks and awards of the Hemophilia and Thrombosis Center Angelo Bianchi Bonomi*

The Hemophilia and Thrombosis  
Center Angelo Bianchi Bonomi is:

International Training Center of the World Federation of Hemophilia

Member of the  
European Thrombosis Research Organisation (ETRO)

Centro di Riferimento della Regione Lombardia  
per i pazienti emofilici e portatori di difetti coagulatori congeniti  
(Reference Center for Regione Lombardia for patients with hemophilia and other  
congenital bleeding disorders).

Centro Fondatore della Federazione dei centri per la sorveglianza  
dei pazienti anticoagulati (FCSA) (Founding Center of the Federation of Centers  
for Surveillance of Anticoagulant Therapy).

## Riconoscimenti del personale del Centro

### *Awards and honours to the staff of the Center*

#### **Pier Mannuccio Mannucci**

- Vice-President Medical, World Federation of Hemophilia, 1978-1992
- Wright-Schulte Memorial Lecture, New York, 1991; Birmingham, 2003
- Editor-in-Chief, Journal of Thrombosis and Haemostasis 1997-2006
- Lecion Conmemorativa A. Raichs, Pamplona, 1995
- President of the International Society on Thrombosis and Haemostasis (ISTH) and of the 16th International ISTH Congress (Florence 1997).
- Distinguished Career Award, International Society for Thrombosis and Haemostasis, Florence 1997.
- Robert Grant Medal Award, International Society for Thrombosis and Haemostasis, Paris, 2001.
- Ham Wasserman Lecture and Award, American Society of Hematology, Philadelphia, 2002
- Medaglia d'oro al merito della Sanità Pubblica, Ministero della Salute, 2005
- Onorificenza di Grande Ufficiale dell'Ordine "al Merito della Repubblica", 2006
- Kwarizmi International Award, Teheran, 2008
- Jean Bernard Lifetime Scientific Award, European Hematology Association, Berlin, 2009

#### **Armando Tripodi:**

- Member of the Scientific and Standardization Committee, International Society on Thrombosis and Haemostasis
- Associate Editor, Journal of Thrombosis and Haemostasis
- Chairman, Italian Federation of Center for Surveillance of Anticoagulant Therapy

#### **Flora Peyvandi:**

- Chair, factor VIII / factor IX Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.



Laboratorio di ricerca del Centro Angelo Bianchi Bonomi

## Unità Cliniche

*Clinical units*

## Emofilia

*Hemophilia*

- **Responsible:**

Alessandro Gringeri, MD, Elena Santagostino, MD, PhD,

Other staff members:

Andrea Artoni, MD

Maria Elisa Mancuso, MD, PhD

Clinical activity: Diagnosis and treatment of patients with congenital and acquired coagulation disorders.

Main research fields: Efficacy and safety of treatments in patients with hemophilia.

Prophylaxis and treatment of blood-transmitted viral infections.

Mechanism and treatment of coagulation factor inhibitors.

## Trombosi

*Thrombosis*

- **Responsible:**

Paolo Bucciarelli, MD, Ida Martinelli, MD, PhD and Marco Moia, MD,

Clinical activity: Diagnosis and treatment of patients with venous thrombosis. Surveillance of oral anticoagulant therapy.

Main research fields: Epidemiology of thromboembolic disorders. Familial thrombotic disorders.

Clinical evaluation of new drugs for prophylaxis and treatment of thrombosis.

## Ambulatorio e day hospital di Ematologia

*Out-patient clinic and Hematology day-hospital*

## Malattia di Von Willebrand e malattie emorragiche rare

*Von Willebrand disease and rare coagulation disorders*

- **Responsible:**

Loredanda Gatti, MD

Clinical activity: Diagnosis and treatment of patients with benign hematological disorders.

- **Responsible:**

Flora Peyvandi, MD, PhD

Clinical activity: Diagnosis and treatment of rare bleeding disorders; diagnosis and treatment of thrombotic microangiopathies.

Main research field: Molecular and laboratory characterization of rare bleeding disorders and thrombotic microangiopathies



Laboratorio di ricerca del Centro Angelo Bianchi Bonomi

## Laboratori

*Laboratories*

## Laboratorio di coagulazione

*Blood coagulation laboratory*

● **Responsible:**

Rossella Bader, senior biologist

Other staff members:

Massimo Boscolo, technician.

Activity: Performs 24 hours a day the laboratory tests necessary for the diagnosis of patients with bleeding and thrombotic disorders and for monitoring their treatment.

## Laboratorio anticoagulanti naturali

*Natural anticoagulants laboratory*

● **Responsible:**

Eugenio Biguzzi, MD

Other staff members:

Franca Franchi, biologist.

Main research fields: Congenital and acquired abnormalities of protein C, protein S, resistance to activated protein C. Hemostasis and thrombosis abnormalities in normal and pathological pregnancies

## Laboratorio malattia di Von Willebrand

*Von Willebrand disease laboratory*

● **Responsible:**

Flora Peyvandi, MD, PhD

Other staff members:

Maria Teresa Canciani, biologist

Luciano Baronciani, biologist

Main research fields: role of von Willebrand factor in hemorrhagic and thrombotic disorders.

## Laboratorio di biologia molecolare

*Molecular biology laboratory*

● **Responsible:**

Flora Peyvandi, MD, PhD

Other staff members:

Rossana Lombardi, biologist

Emanuela Pappalardo, biologist

Clinical activity: Prenatal diagnosis of hemophilia and hemorrhagic diseases.

Main research fields: Molecular genetics of congenital thrombophilic states. Markers of thrombophilia.

Molecular and clinical aspects of rare coagulation disorders. Molecular and clinical aspects of thrombotic microangiopathies

## Laboratorio di nuove metodiche

*Development of new laboratory methods*

● **Responsible:**

Armando Tripodi, PhD

Other staff members:

Veena Chantarangkul, technician.

Giuliana Merati, biologist

Activity: Development of new laboratory methods. Standardization of reagents. Quality controls.

Main research fields: Near-patient testing systems in coagulation. Standardization of anticoagulant therapy. Predictive values of coagulation tests.

## Laboratorio della funzione piastrinica

*Platelet function laboratory*

● **Responsible:**

Andrea Artoni, MD

Other staff members:

Anna Lecchi, biologist

Main research fields: platelet function in hemorrhagic and thrombotic disorders.

## Elenco dei Dottorandi

### *PhD Students*

- Isabella Garagiola  
Roberta Palla  
Simona Siboni  
Marzia Menegatti  
Luca Lotta  
Serena Passamonti

## Elenco dei Borsisti della Fondazione anni 2005 - 2010

*Research fellowships of the Foundation,  
years 2005 - 2010*

- 2005  
Isabella Garagiola  
Silvia Lavoretano  
Marzia Menegatti  
Marta Spreafico  
Liliana Tagliabue
- 2006  
Bettina Oliviero  
Valentina Rubini
- 2007  
Carla Valsecchi  
Roberta Palla
- 2009  
Simon V.M. Brahm
- 2010  
Marigrizia Clerici  
Andrea Cairo

**co**  
**qu**

935. Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, Pengo V, Ghirarduzzi A, Pattacini C, Testa S, Lensing AWA, Tripodi A, for the PROLONG Investigator. D-dimer testing to determine the duration of anticoagulation therapy.  
**New England Journal of Medicine** 2006; **355**: 1780-1789.
936. Zwicker JI, Peyvandi F, Palla R, Lombardi R, Canciani MT, Cairo A, Ardissono D, Bernardinelli L, Bauer KA, Lawler J, Mannucci PM. The thrombospondin-1 N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor multimer size.  
**Blood** 2006; **1280**-1283.
937. Zhang B, McGee B, Yamaoka JS, Guglielmino H, Downes KA, Minoldo S, Jarchum G, Peyvandi F, de Bosch NB, Ruiz-Saez A, Chatelain B, Olpinski M, Bockenstedt P, Sperl W, Kaufman RJ, Nichols WC, Egd T, Ginsburg D. Combined deficiency of factor V and factor VIII is due to mutations in either LMAN1 or MCFD2.  
**Blood** 2006; **107**:1903-1907.
938. Zivelin A, Mor-Cohen R, Kovalsky V, Kornbrot N, Conard J, Peyvandi F, Kyrie PA, Bertina R, Peyvandi F, Emmerich J, Seligsohn U. Prothrombin G20210A is an ancestral prothrombotic mutation that occurred in Caucasians approximately 24,000 years ago.
939. Federici AB. Impaired megakaryocytopoiesis in type 2B von Willebrand disease.  
**Blood** 2006; **108**: 2498-2499.
940. Ruggeri ZM, Orje JN, Habermann R, Federici AB, Reininger AJ. Activation-independent platelet adhesion and aggregation under elevated shear stress.  
**Blood** 2006; **108**: 1903-1910.
941. Tripodi A, Primignani M, Chantarangkul V, Clerici M, Dell'Era A, Frabris F, Salerno F, Mannucci PM. Thrombin generation in patients with cirrhosis: the role of platelets.  
**Hepatology** 2006; **44**:440-445.
942. Primignani M, Barosi G, Bergamaschi G, Gianelli U, Fabris F, Reati R, Dell'Era A, Buccarelli P, Mannucci PM. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis.  
**Hepatology** 2006; **44**: 1528-34.
943. Caldwell SH, Hoffman M, Lisman T, Macik BG, Northup PG, Reddy KR, Tripodi A, Sanyal AJ, Coagulation in Liver Disease Group. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management.  
**Hepatology** 2006; **44**: 1039-1046
944. Peyvandi F, Lavoretano S, Palla R, Valsecchi C, Merati G, De Cristofaro R, Rossi E, Mannucci PM. Mechanisms of the interaction between two ADAMTS13 gene mutations leading to severe deficiency of enzymatic activity.  
**Human Mutation** 2006. **27**:330-336.
945. Asero R, Tedeschi A, Riboldi P, Cugno M. Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intra-dermal injection causes wheal-and-flare reactions much more frequently than autologous serum.  
**Journal of Allergy and Clinical Immunology** 2006; **117**: 1113-1117.
946. Agnelli G, Bolis G, Capussotti L, Scarpa RM, Tonelli F, Bonizzoni E, Moia M, Parazzini F, Rossi R, Sonaglia F, Valarani B, Bianchini C, Gussoni G. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project.  
**Annals of Surgery** 2006;243:89-95.
947. De Cristofaro R, Peyvandi F, Baronciani L, Palla R, Lavoretano S, Lombardi R, Di Stasio E, Federici AB, Mannucci PM. Molecular mapping of the chloride binding site in von Willebrand factor (VWF): energetics and conformational effects on the VWF/ADAMTS1-13.  
**Journal of Biological Chemistry** 2006;

**281: 30400-30411**

948. Kunicki TJ, Baronciani L, Canciani MT, Gianniello F, Head SR, Mondala TS, Salomon DR, Federici AB. An association of candidate gene haplotypes and bleeding severity in von Willebrand disease type 2A, 2B, and 2M pedigrees. *Journal of Thrombosis and Haemostasis* 2006;4:137-147.

949. Castaman G, Federici AB, Bernardi M, Moroni B, Bertoncello K, Rodeghiero F. Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective study comparing patients with single (R1205H) and double (R1205H-M740I) defect. *Journal of Thrombosis and Haemostasis* 2006;4:357-360.

950. Santagostino E, Mancuso ME, Rocino A, Mancuso G, Scaraggi F, Mannucci PM. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. *Journal of Thrombosis and Haemostasis* 2006;4:367-371.

951. Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Battle J, Meyer D, Fressinaud E, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Budde U, Ingerslev J, Vorlova Z, Habart D, Homberg L, Lethagen S, Pasi J, Hill F, Peake I. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). *Journal of Thrombosis and Haemostasis* 2006;4:766-773.

952. Chantarangkul V, van den Besselaar AM, Witteveen E, Tripodi A. International collaborative study for the calibration of a proposed international standard for thromboplastin, rabbit, plain. *Journal of Thrombosis and Haemostasis* 2006; 4: 1339-1345.

953. Saibeni S, Ciscato C, Vecchi M, Boscolo Anzoletti M, Kaczmarek E, Caccia S, De Franchis R, Cugno M. Antibodies to tissue-type plasminogen activator (tPA) in patients with inflammatory bowel disease: high prevalence, interaction with functional domains of tPA and possible implications in thrombosis. *Journal of Thrombosis and Haemostasis* 2006; 4: 1510-1516.

954. Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peaker IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR, Federici AB, the Working Party on von Willebrand Disease Classification.

Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.

*Journal of Thrombosis and Haemostasis* 2006; 4: 2103-2114.

955. Martinelli I, Battaglioli T, Tosetto A, Legnani C, Sottile L, Ghiootto R, Mannucci PM. Prothrombin A19911G polymorphism and the risk of venous thromboembolism. *Journal of Thrombosis and Haemostasis* 2006; 4: 2582-2586.

956. Castaman G, Rodeghiero F, Tosetto A, Cappelletti A, Baudo F, Eikenboom JC, Federici AB, Lethagen S, Linari S, Lusher J, Nishino M, Petrini P, Srivastava A, Ungerstedt JS. Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study. *Journal of Thrombosis and Haemostasis* 2006; 4: 2164-2169

957. Mannucci PM. Editorial. *Journal of Thrombosis and Haemostasis* 2006;4:1-2.

958. Mannucci PM. Need for randomized trials in hemophilia. *Journal of Thrombosis and Haemostasis* 2006;4:501-502.

959. Mannucci PM. Abnormal he-

mostasis tests and bleeding in chronic liver disease: are they related? No. *Journal of Thrombosis and Haemostasis* 2006;4:721-723.

960. Tripodi A, Mannucci PM. Activated partial thromboplastin (APTT). New indications for an old test? *Journal of Thrombosis and Haemostasis* 2006;4:750-751.

961. Medcalf RL, Mannucci PM. A tale of two societies. *Journal of Thrombosis and Haemostasis* 2006; 4: 1173-1174.

962. Tripodi A. Hemostasis in chronic liver disease. *Journal of Thrombosis and Haemostasis* 2006; 4: 2064-2065

963. Crotti A, Neri F, Corti D, Ghezi S, Heltai S, Bauer A, Poli G, Santagostino E, Vicenzi E. New alleles from HIV-1-infected long-term non-progressor hemophiliacs with or without late disease progression are defective in enhancing virus replication and CD4 down regulation. *Journal of Virology* 2006; 80: 10663-10674

964. Federici AB, Santagostino E, Rumi MG, Russo A, Mancuso ME, Soffredini R, Mannucci PM, Colombo M. The natural history of hepatitis C virus infection in Italian patients with von Willebrand's disease: a cohort study.

**Haematologica 2006; 91: 503-508**

965. Rocino A, Santagostino E, Mancuso ME, Mannucci PM. Immune tolerance induction with recombinant factor VIII in hemophilia A patients with high responding inhibitors.

**Haematologica 2006; 91: 558-561**

966. Monaldini L, Asselta R, Duga S, Peyvandi F, Ghosh K, Malcovati M, Tenchini ML. Fibrinogen Mumbai: intracellular retention due to a novel G434D mutation in the Bbeta-chain gene.

**Haematologica 2006; 91: 628-633.**

967. Santagostino E, Mancuso ME, Morfini M, Schiavoni M, Tagliaferri A, Barillari G, Mannucci PM. Solvent/detergent plasma for prevention of bleeding in recessively inherited coagulation disorders: dosing; pharmacokinetics and clinical efficacy.

**Haematologica 2006; 91: 634-639.**

968. Martinelli I, Battaglioli T, Burgo I, Di Domenico S, Mannucci PM. Oral contraceptive use, thrombophilia and their interaction in young women with ischemic stroke.

**Haematologica 2006; 91: 844-847.**

969. Mancuso ME, Rumi MG, Santagostino E, Linari S, Coppola A, Mannucci PM, Colombo M, Hepatitis Study Group of the Association of Italian Hemophilia Center. High effica-

cy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C.

**Haematologica 2006; 91: 1367-1371.**

970. Imberti D, Ageno W, Carpenedo M. Retrievable vena cava filters: a review.

**Current Opinion in Hematology 2006; 13: 351-356.**

971. Battaglioli T, Gorini G, Costantini AS, Crosignani P, Miligi L, Nannic O, Stagnaro E, Tumino R, Vineis P. Cigarette smoking and alcohol consumption as determinants of surviving non-Hodgkin's lymphoma: a population-based study.

**Annals of Oncology 2006; 17: 1283-1289.**

972. Minuz P, Fumagalli L, Gaino S, Tommasoli RM, Degan M, Cavalini C, Lecchi A, Cattaneo M, Lechi Santonastaso C, Berton G. Rapid stimulation of tyrosine phosphorylation signals downstream of G protein-coupled receptors for thromboxane A2 in human platelets.

**Biochemistry Journal 2006; 127-134**

973. Peyvandi F, Siboni SM, Lambertenghi Deliliers D, Lavoretano S, De Fazio N, Moroni B, Lambertenghi Deliliers G, Mannucci PM. Prospective study on the behaviors of the metalloprotease ADAMTS13 and of von Willebrand factor after bone marrow transplantation.

**British Journal of Haematology 2006; 134: 187-195**

974. Di Stefano V, Martinelli I, Rossi F, Battaglioli T, Za T, Mannucci PM. The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis.

**British Journal of Haematology 2006; 135: 386-391**

975. Federici AB. Acquired von Willebrand syndrome: an underdiagnosed and misdiagnosed bleeding complication in patients with lymphoproliferative and myeloproliferative disorders.

**Seminars in Hematology 2006; 43: S48-S58.**

976. Palmieri O, Latiano A, Valvano R, D'Inca R, Vecchi M, Sturniolo GC, Saibeni S, Peyvandi F, Bossa F, Zagaria C, Andriulli A, Devoto M, Annese V. Variants of OCTN1-2 action transporter genes are associated with both Crohn's disease and ulcerative colitis.

**Alimentary Pharmacology and Therapeutics 2006; 23: 497-506.**

977. Binetti BM, Rotunno C, Tripodi A, Asti D, Semeraro F, Semeraro N, Colucci M. Hyperprothrombinemia-induced APC resistance: differential influence on fibrin formation and fibrinolysis.

**Thrombosis and Haemostasis 2006;**

**95: 606-611.**

978. Linsinger TP, van den Beselaar AM, Tripodi A. Long-term stability of relationship between reference materials for thromboplastins.

**Thrombosis and Haemostasis 2006; 96: 210-214.**

979. Franchi F, Viscardi Y, Razza Zari C, Faioni EM, Bonara P, Bignuzzi E, Mannucci PM. C.301C>T (p.Arg101Cys): a novel mutation in the thrombin-sensitive region of protein S associated with a dysfunctional protein.

**Thrombosis and Haemostasis 2006; 96: 381-383.**

980. Meijer P, Kluft C, Poller L, van der Meer FJ, Keown M, Ibrahim S, van den Besselaar AM, Tripodi A, Jespersen J. A national field study of quality assessment of CoaguChek point-of-care testing prothrombin time monitors.

**American Journal of Clinical Pathology 2006; 126: 756-761.**

981. Einhaupl K, Bousser MG, Brujin SF, Ferro JM, Martinelli I, Maisch F, Stam J. EFNS guideline on the treatment of cerebral venous and sinog thrombosis.

**European Journal of Neurology 2006; 13: 553-559.**

982. Berntorp E, Gringeri A, Leis-

singer C, Negrier C, Key N. New approaches to using FEIBA in the treatment of inhibitor patients. **Seminars in Thrombosis and Haemostasis 2006; 32: 22-27**

983. Valentino LA, Santagostino E, Blanchette V, Van den Berg M. Managing the pediatric patient and the adolescent/adult transition. **Seminars in Thrombosis and Haemostasis 2006; 32: 28-31**

984. Federici AB. Diagnosis of inherited von Willebrand disease: a clinical perspective. **Seminars in Thrombosis and Haemostasis 2006; 32: 555-565**

985. Federici AB. Management of inherited von Willebrand disease in 2006. **Seminars in Thrombosis and Haemostasis 2006; 32: 616-620**

986. Martinelli I. Thromboembolism in women. **Seminar in Thrombosis and Haemostasis 2006; 32: 709-715**

987. Gringeri A, Monzini M, Tagariello G, Scaraggi FA, Mannucci PM. Occurrence of inhibitors in previously untreated or minimally treated patients with hemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate. **Haemophilia 2006;12:128-132.**

988. Scalzone L, Mantovani LG, Mannucci PM, Gringeri A. Quality of life is associated to the orthopedic status in hemophilic patients with inhibitors. **Haemophilia 2006;12:154-162.**

989. Gringeri A, Mantovani L, von Mackensen S. Quality of life assessment in clinical practice in hemophilia treatment. **Haemophilia 2006;12 (S3):22-29.**

990. Lillicrap D, Nair SC, Srivastava A, Rodeghiero F, Pabinger I, Federici AB. Laboratory issues in bleeding disorders. **Haemophilia 2006;12 (S3):68-75.**

991. Barrowcliffe TW, Cattaneo M, Podda GM, Bucciarelli P, Lussana F, Lecchi A, Toh CH, Hemker HC, Beguin S, Ingerslev J, Sorensen B. New approaches for measuring coagulation. **Haemophilia 2006;12 (S3):76-81.**

992. Peyvandi F, Jayandharan G, Chandy M, Srivastava A, Nakaya SM, Johnson MJ, Thompson AR, Goodeve A, Garagiola I, Lavoretano S, Menegatti M, Palla R, Spreafico M, Tagliabue L, Asselta R, Duga S, Mannucci PM. Genetic diagnosis of hemophilia and other inherited bleeding disorders. **Haemophilia 2006;12 (S3):82-89.**

993. Solimeno LP, Perfetto OS,

Pasta G, Santagostino E. Total joint replacement in patients with inhibitors.

**Haemophilia 2006; 12 (S3): 113-116.**

994. Peyvandi F, Kaufman RJ, Seligsohn U, Salomon O, Bolton-Maggs PH, Spreafico M, Menegatti M, Palla R, Siboni S, Mannucci PM. Rare bleeding disorders. **Haemophilia 2006;12 (S3):137-142.**

995. Astermark J, Morado M, Rocino A, van Den Berg HM, von Depka M, Gringeri A, Mantovani L, Garrido RP, Schiavoni M, Villar A, Windyga J, on behalf of the EHTSB. Current European practice in immune tolerance induction therapy in patients with hemophilia and inhibitors. **Haemophilia 2006, 12: 363-371.**

996. Mannucci PM, Abshire T, Dimichele D, Santagostino E, Blanchette V. Inhibitor development, immune tolerance and prophylaxis in hemophilia A – the need for an evidence-based approach. **Haemophilia 2006, 12: 429-434.**

997. Federici AB, Castaman G, Thompson A, Berntorp E. Von Willebrand's disease: clinical management. **Haemophilia 2006; 12 (S3): 152-158.**

998. Federici AB, Berntorp E, Lee CA. The 80th anniversary of von Willebrand's disease: history, manage-

ment and research.

**Haemophilia 2006; 12: 563-572.**

999. Khalife H, Muwakkit S, Al Moussawi H, Dabbous I, Khoury R, Peyvandi F, Abboud MR. Spontaneous splenic rupture in a patient with factor XIII deficiency and a novel mutation. **Pediatric Blood and Cancer 2006; online**

1000. Loffredo G, Baronciani L, Noris P, Menna F, Federici AB, Balduini CL. Von Willebrand disease type 2B must be always considered in the differential diagnosis of genetic thrombocytopenias with giant platelets. **Platelets 2006; 17: 149-152**

1001. De Cristofaro R, Carotti A, Akhavan S, Palla R, Peyvandi F, Altomare C, Mannucci PM.

The natural mutation by deletion of Lys9 in the thrombin A-chain affects the pKa value of catalytic residues, the overall enzyme's stability and conformational transitions linked to Na<sup>+</sup> binding. **FEBS J 2006;273:159-169.**

1002. Karimi M, Sabzi A, Peyvandi F, Mannucci PM.

Clinical and laboratory patterns of the haemolytic uremic syndrome and thrombotic thrombocytopenic purpura in southern Iran. **Internal Emergency Medicine 2006; 1: 35-39.**

1003. Fiandaca D, Bucciarelli P, Martinelli I, Tantardini F, Clemente C, Mannucci PM. Psychological impact of thrombosis in the young.  
**Internal Emergency Medicine 2006; 2: 119-126.**
1004. Mannucci PM. Thrombotic thrombocytopenic purpura: another example of immunomediated thrombosis.  
**Pathophysiology in Haemostasis and Thrombosis 2006; 35 (1-2): 89-97. (I.F. 0.98)**
1005. Mannucci PM, Federici AB. Von Willebrand disease: the 80th anniversary.  
**Hematology 2006; 2: 224-230.**
1006. Tavazzi L, Garattini S, Mannucci PM, Remuzzi G. Considerations on clinical drug research in Italy.  
**Giornale Italiano di Cardiologia 2006; 7: 62-67**
1007. Franchi F, Martinelli I, Biguzzi E, Bucciarelli P, Mannucci PM. Marburg I polymorphism of factor VII-activating protease and risk of venous thromboembolism.  
**Blood 2006;107:1731. (letter).**
1008. Mannucci PM. Assessing the risk of inhibitor formation with different factor VIII products.  
**Blood 2006; 107: 3809-3810. (letter).**
1009. Razzari C, Franchi F, Biguzzi E, PROSIT. Protein S binding to phospholipids: evaluation of eight variants of recombinant human protein S from the PROSIT study.  
**Journal of Thrombosis and Haemostasis 2006;4:273-274. (letter)**
1010. Sacco R, Sacco M, Carpenedo M, Moia M. Oral surgery in patients on oral anticoagulant therapy: a randomized comparison of different INR targets.  
**Journal of Thrombosis and Haemostasis 2006;4:688-689. (letter)**
1011. Karimi M, Sabzi A, Peyvandi F, Mannucci PM. Changing epidemiology of the hemolytic uremic syndrome and thrombotic thrombocytopenic purpura in southern Iran.  
**Journal of Thrombosis and Haemostasis 2006;4:701-702. (letter)**
1012. Eikenboom J, van Marion V, Putter H, Goedewe A, Rodeghiero F, Castaman G, Federici AB, Batkle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R, Budde Y, Ingerslev J, Volova Z, Habart D, Homberg L, Lethagen S, Pasi J, Hill F, Peake I. Linkage analysis in families diagnosed with type 1 von Willebrand in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD.  
**Journal of Thrombosis and Haemostasis 2006;4:774-782 (letter).**
1013. Mannucci PM, Bohm M, Scharrer I, Scheiflinger F. Patterns of changes of anti-ADAMTS13 after plasma exchange.  
**Journal of Thrombosis and Haemostasis 2006; 4: 1405-1406. (letter)**
1014. Tripodi A, Chantarangkul V, Asti D, Martinelli I, Mannucci PM. Activated partial thromboplastin time: results of a case-control study evaluating six commercial reagents in assessing the risk of venous thromboembolism.  
**Journal of Thrombosis and Haemostasis 2006; 4: 1407-1409 (letter).**
1015. Peyvandi F, Haertel S, Knaub S, Mannucci PM. Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia.  
**Journal of Thrombosis and Haemostasis 2006; 4: 1634-1937. (letter)**
1016. Ludlam CA, Mannucci PM. Proposal to establish a European Association for Haemophilia and Allied Disorders.  
**Journal of Thrombosis and Haemostasis 2006; 4: 2270-2271. (letter)**
1017. Baronciani L, Federici AB, Cozzi G, Canciani MT, Mannucci PM. von Willebrand factor collagen binding assay in von Willebrand disease type 2A, 2B, and 2M.  
**Journal of Thrombosis and Haemostasis 2006; 4: 2088-2090. (letter)**
1018. Grandone E, Martinelli I, Margaglione M, Dragani A, Davi G. Platelet activation in subjects carrying factor V Leiden or factor II A20210 mutations.  
**Journal of Thrombosis and Haemostasis 2006; 4: 2496-8 (letter)**
1019. Lussana F, Faioni EM, Mavilia C, Bucciarelli P, Brandi ML, Cataneo M. Association of estrogen receptor-alpha gene polymorphisms with venous thrombosis.  
**Haematologica 2006;91:279-280. (letter).**
1020. Franchi F, Viscardi Y, Cetin I, Bucciarelli I, Martinelli I, Biguzzi E. Annexin VC/T-1 polymorphism and pregnancy complications.  
**Haematologica 2006; 91: 864. (letter)**
1021. Santagostino E, Mannucci PM. Protective effect of prophylaxis on inhibitor development in children with hemophilia A.  
More convincing studies are required.  
Response to Calvez and Laurian.  
**British Journal of Haematology 2006; 132: 800-801. (letter)**
1022. Razzari C, Martinelli I, Bucciarelli P, Viscardi Y, Biguzzi E. Polymorphisms of the protein Z-dependent protease inhibitor (ZPI) gene and the risk of venous thromboembolism.  
**Thrombosis and Haemostasis 2006; 95: 909-910 (letter).**



1023. Mannucci PM, Levi M. Prevention and treatment of major blood loss.

**New England Journal of Medicine**  
**2007; 356: 2301-2311.**

1024. The van Gogh Investigators\* (\*Appendix: P.M. Mannucci, I. Martinelli). Idaraparinix versus standard therapy for venous thromboembolic disease.

**New England Journal of Medicine**  
**2007; 356: 1094-1104.**

1025. The van Gogh Investigators\* (\*Appendix: P.M. Mannucci, I. Martinelli, T. Battaglioli). Extended prophylaxis of venous thromboembolism with idaraparinix.

**New England Journal of Medicine**  
**2007; 356: 1105-1112.**

1026. Tripodi A, Chantarangkul V, Primignani M, Fabris F, Dell'Era A, Sei C, Mannucci PM. The international normalized ratio calibrated for cirrhosis (INRliver) normalizes prothrombin time results for model for end-stage liver disease calculation.

**Hepatology** **2007; 46: 520-527**

1027. Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, Berntorp E; FENOC Study Group. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.

**Blood** **2007; 109: 546-551.**

1028. Goodeve A, Eikenboom J, Castaman G, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R, Budde U, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J, Hill F, Hashemi Soteh M, Baronciani L, Hallden C, Guillatt A, Lester W, Peake I.

Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMMD-1VWD).

**Blood** **2007;109:112-121.**

1029. Asero R, Tedeschi A, Coppoli R, Griffini S, Paparella P, Riboldi P, Marzano AV, Fanoni D, Cugno M. Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria.

**Journal of Allergy and Clinical Immunology** **2007; 119: 705-710.**

1030. Maggio M, Lauretani F, Ceda GP, Bandinelli S, Ling SM, Metter EJ, Artoni A, Carassale L, Cazzato A, Ceresini G, Guralnik JM, Basaria S, Valenti G, Ferrucci L. Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the Chianti Area (InCHIANTI) study.

**Archives of Internal Medicine**  
**2007;167:2249-2254**

1031. Vanuzzo D, Pilotto L, Lombardi R, Lazzerini G, Carluccio M, Diviaco S, Quadrioglio F, Danek G, Gregori D, Fioretti P, Cattaneo M, De Caterina R. Both vitamin B6 and total homocysteine plasma levels predict long-term atherothrombotic events in healthy subjects.

**European Heart Journal** **2007; 28: 484-491.**

1032. Pierangeli SS, Vega-Ostertag ME, Raschi E, Liu X, Romay-Penabad Z, De Micheli V, Galli M, Moia M, Tinacci A, Borghi MO, Nguyen-Oghalai T, Meroni PL. Toll like receptor 4 is involved in antiphospholipid- mediated thrombosis: In vivo studies. 1:

**Annals of Rheumatic Diseases**  
**2007; 66: 1327-33**

1033. Rovida E, Merati G, D'Ursi P, Zanardelli S, Marino F, Fontana G, Castaman G, Faioni EM. Identification and computationally-based structural interpretation of naturally occurring variants of human protein C.

**Human Mutation** **2007;28:345-355**

1034. Tripodi A, Mannucci PM. Abnormalities of hemostasis in chronic liver disease: Reappraisal of their clinical significance and need for clinical and laboratory research.

**Journal of Hepatology** **2007; 46: 727-733.**

1035. Baccarelli A, Zanobetti A, Martinelli I, Grillo P, Hou L, Lanzani G, Mannucci PM, Bertazzi PA, Schwartz J. Air pollution, smoking, and plasma homocysteine. *Environmental Health and Perspectives* 2007;115:176-181.
1036. Tripodi A. Laboratory testing for lupus anticoagulants: a review of issues affecting results. *Clinical Chemistry* 2007;53:1629-1635.
1037. Battaglioli T, Martinelli I. Hormone therapy and thromboembolic disease. *Current Opinion in Hematology* 2007;14:488-93.
1038. Martinelli I, Battaglioli T, Razzari C, Mannucci PM. Type and location of venous thromboembolism in patients with factor V Leiden or prothrombin G20210A and in those with no thrombophilia. *Journal of Thrombosis and Haemostasis* 2007; 5: 98-101.
1039. Baronciani L, Federici AB, Cozzi G, Canciani MT, Mannucci PM. Biochemical characterization of a recombinant von Willebrand factor (VWF) with combined type 2B and type 1 defects in the VWF gene in two patients with a type 2A phenotype of von Willebrand disease. *Journal of Thrombosis and Haemostasis* 2007;5:282-288.
1040. Baccarelli A, Zanobetti A, Martinelli I, Grillo P, Hou L, Giacomini S, Bonzini M, Lanzani G, Mannucci PM, Bertazzi PA, Schwartz J. Effects of exposure to air pollution on blood coagulation. *Journal of Thrombosis and Haemostasis* 2007;5:252-260.
1041. Mannucci PM, Roberts HR. At the end of the first 3 years. *Journal of Thrombosis and Haemostasis* 2007; 5: 445-447.
1042. Cattaneo M, Lecchi A. Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin. *Journal of Thrombosis and Haemostasis* 2007; 5: 577-582.
1043. Tosetto A, Rodeghiero F, Castaman G, Bernardi M, Bertoncello K, Goodeve A, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Budde U, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill F, Peake I. Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study [MCM-DM-1VWD]. *Journal of Thrombosis and Haemostasis* 2007; 5: 715-721.
1044. Schneppenheim R, Casta- man G, Federici AB, Kreuz W, Marschalek R, Oldenburg J, Oyen F, Budde U. A common 253-kb deletion involving VWF and TMEM16B in German and Italian patients with severe von Willebrand disease type 3. *Journal of Thrombosis and Haemostasis* 2007; 5: 722-728.
1045. Borel-Derlon A, Federici AB, Roussel-Robert V, Goudemand J, Lee CA, Scharrer I, Rothschild C, Berntorp E, Henriet C, Tellier Z, Bridley F, Mannucci PM. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. *Journal of Thrombosis and Haemostasis* 2007;5:1115-1124
1046. Poller L, Keown M, Ibrahim S, van den Besselaar AM, Roberts C, Stevenson K, Tripodi A, Pattison A, Jespersen J; on behalf of the European Action on Anticoagulation. Comparison of local ISI calibration and "direct INR" methods in correction of locally reported international normalized ratios: an international study. *Journal of Thrombosis and Haemostasis* 2007; 5: 1002-1009
1047. Lethagen S, Kyrle PA, Castaman G, Haertel S, Mannucci PM; the Haemate P Surgical Study Group. Von Willebrand factor/factor VIII concentrate (Haemate(R) P) do- sing based on pharmacokinetics: a prospective multicenter trial in elective surgery. *Journal of Thrombosis and Haemostasis* 2007; 5: 1420-1430
1048. Pengo V, Biasiolo A, Gresele P, Marongiu F, Erba N, Veschi F, Ghirarduzzi A, de Candia E, Montaruli B, Testa S, Barcellona D, Tripodi A; Participating Centers of Italian Federation of Thrombosis Centres (FCSA). Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples. *Journal of Thrombosis and Haemostasis* 2007;5:925-930.
1049. Mannucci PM. Thrombosis and bleeding disorders outside Western countries. *Journal of Thrombosis and Haemostasis* 2007;5 (S1):68-72.
1050. Meroni PL, Peyvandi F, Foco L, Bernardinelli L, Fetiveau R, Mannucci PM, Tincani A. Anti-beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women. *Journal of Thrombosis Haemostasis* 2007;5:2421-2428.
1051. Franchini M, Mannucci PM. Short-term effects of air pollution on cardiovascular diseases: outcomes and mechanisms. *Journal of Thrombosis and Haemostasis* 2007;5:2169-2174.

1052. Podda GM, Buccarelli P, Lussana F, Lecchi A, Cattaneo M. Usefulness of PFA-100 testing in the diagnostic screening of patients with suspected abnormalities of hemostasis: comparison with the bleeding time.  
**Journal of Thrombosis and Haemostasis** 2007;5:2393-2398.
1053. Cattaneo M, Lecchi A, Zighetti ML, Lussana F. Platelet aggregation studies: autologous platelet-poor plasma inhibits platelet aggregation when added to platelet-rich plasma to normalize platelet count.  
**Haematologica** 2007;92:694-697.
1054. Federici AB, Castaman G, Franchini M, Morfini M, Zanon E, Coppola A, Tagliaferri A, Boeri E, Mazzucconi MG, Rossetti G, Mannucci PM. Clinical use of Haemate[R]P in inherited von Willebrand's disease: a cohort study on 100 Italian patients.  
**Haematologica** 2007;92:944-951.
1055. Mannucci PM. Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome: much progress and many remaining issues.  
**Haematologica** 2007;92:878-880.
1056. Hron G, Lombardi R, Eichinger S, Lecchi A, Kyrle PA, Cattaneo M. Low vitamin B6 levels and the risk of recurrent venous thromboembolism.  
**Haematologica** 2007;92:1254-1257.
1057. Federici AB, Mannucci PM. Management of inherited von Willebrand disease in 2007.  
**Annals of Medicine** 2007;39:346-358.
1058. Feys HB, Canciani MT, Peyvandi F, Deckmyn H, Vanhoorelbeke K, Mannucci PM. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis.  
**British Journal of Haematology** 2007; 138:534-540
1059. Asero R, Riboldi P, Tedeschi A, Cugno M, Meroni P. Chronic urticaria: a disease at a crossroad between autoimmunity and coagulation.  
**Autoimmunity Reviews** 2007;7: 71-76
1060. Tripodi A, Caldwell SH, Hoffman M, Trotter JF, Sanyal AJ. Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease.  
**Alimentary Pharmacology & Therapeutic** 2007;26:141-148
1061. Di Paola J, Smith MP, Klamroth R, Mannucci PM, Kollmer C, Feingold J, Kessler C, Pollmann H, Morfini M, Udata C, Rothschild C, Hermans C, Janco R. ReFacto and Advate: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A.  
**Haemophilia** 2007;13:124-130.
1062. Astermark J, Rocino A, Von Depka M, Van Den Berg HM, Gringeri A, Mantovani LG, Morado M, Garrido RP, Schiavoni M, Villar A, Windyga J; EHTSB. Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors.  
**Haemophilia** 2007; 13:38-45.
1063. Teitel J, Berntorp E, Collins P, D'Oiron R, Ewenstein B, Gomperts E, Goudemand J, Gringeri A, Key N, Leissinger C, Monahan P, Young G. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors.  
**Haemophilia** 2007;13:256-263.
1064. Jayandharan G, Spreafico M, Viswabandya A, Chandy M, Srivastava A, Peyvandi F. Mutations in the MCFD2 gene are predominant among patients with hereditary combined FV and FVIII deficiency (F5F8D) in India.  
**Haemophilia** 2007;13:413-419.
1065. Gringeri A, Musso R, Mazzucconi MG, Pischeddu G, Schiavoni M, Pignoloni P, Mannucci PM; FOR THE RITS-FITNHS STUDY GROUP. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response.  
**Haemophilia** 2007;13:373-379.
1066. DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations.  
**Haemophilia** 2007; 13(s1): 1-22.
1067. Federici AB. Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO.WILL Study.  
**Haemophilia** 2007;13 (S5):15-24.
1068. Mannucci PM, Gringeri A, Peyvandi F, Santagostino E. Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers).  
**Haemophilia** 2007;13 (S5):65-68.
1069. Gringeri A. VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study.  
**Haemophilia** 2007;13 (S5):73-7
1070. Gianelli U, Vener C, Raviele PR, Savi F, Somalvico F, Calori R, Iurillo A, Radaelli F, Fermo E, Buccarelli P, Bori S, Coggi G, Deliliers GL. VEGF expression correlates with microvesSEL density in Philadelphia chromosome-negative chronic myeloproliferative disorders.  
**American Journal of Clinical Pathology** 2007;128:966-973
1071. Monaldini L, Asselta R, Duoga S, Peyvandi F, Karimi M, Malcova-

ti M, Tenchini ML. Mutational screening of six afibrinogenemic patients: Identification and characterization of four novel molecular defects.

**Thrombosis and Haemostasis 2007; 97: 546-551.**

1072. Morsica G, Bagaglio S, Ghezzi S, Lodrini C, Vicenzi E, Santagostino E, Gringeri A, Cusini M, Carminati G, Bianchi G, Galli L, Lazzarin A, Poli G. Hepatitis C virus (HCV) coinfection in a cohort of HIV positive long-term non-progressors: Possible protective effect of infecting HCV genotype on HIV disease progression.

**Journal of Clinical Virology 2007; 39:82-86.**

1073. Podda GM, Lussana F, Moroni G, Faioni EM, Lombardi R, Fontana G, Ponticelli C, Maioli C, Cattaneo M. Abnormalities of homocysteine and B vitamins in the nephrotic syndrome.

**Thrombosis Research 2007;120: 647-652**

1074. Biguzzi E, Franchi F, Bucciarrelli P, Colombo M, Romeo R. Endothelial protein C receptor plasma levels increase in chronic liver disease, while thrombomodulin plasma levels increase only in hepatocellular carcinoma.

**Thrombosis Research 2007;120: 289-293.**

1075. Pengo V, Biasiolo A, Bison E, Chantarangkul V, Tripodi A; Italian

Federation of Anticoagulation Clinics (FCSA). Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-beta2-Glycoprotein I activity.

**Thrombosis Research 2007;120: 127-133.**

1076. Castaman G, Biguzzi E, Razzaari C, Tosetto A, Fontana G, Asti D, Brancaccio V, Castori D, Lane DA, Faioni EM; for the ProSIT (Protein S Italian Team). Association of protein S p.Pro667Pro dimorphism with plasma protein S levels in normal individuals and patients with inherited protein S deficiency.

**Thrombosis Research 2007;120: 421-426.**

1077. Tripodi A, Martinelli I, Chantarangkul V, Battaglioli T, Clerici M, Mannucci PM. The endogenous thrombin potential and the risk of venous thromboembolism.

**Thrombosis Research 2007;121: 353-359.**

1078. Saiben S, Spina L, Virgilio T, Folcioni A, Borsi G, de Franchis R, Cugno M, Vecchi M. Angiotensin-converting enzyme insertion/deletion gene polymorphism in inflammatory bowel diseases.

**European Journal of Gastroenterology and Hepatology 2007;19: 976-981.**

1079. Afrasiabi A, Lecchi A, Artoni A, Karimi M, Ashouri E, Peyvandi F, Mannucci PM. Genetic characterization of patients with Bernard-Soulier syndrome and their relatives from Southern Iran.

**Platelets 2007;18:409-13.**

1080. Sozzi FB, Danzi GB, Foco L, Ferlini M, Tubaro M, Galli M, Celli P, Mannucci PM. Myocardial infarction in the young: a sex-based comparison.

**Coronary Artery Disease 2007;18: 429-431.**

1081. Siboni SM, Spreafico M, Menegatti M, Martinelli I, Peyvandi F. Molecular characterization of an Italian patient with plasminogen deficiency and ligneous conjunctivitis.

**Blood Coagulation and Fibrinolysis 2007;18: 81-84.**

1082. Tripodi A, Asti D, Chantarangkul V, Biguzzi E, Mannucci PM. Interference of factor V Leiden on protein S activity: evaluation of a new prothrombin time-based assay.

**Blood Coagulation and Fibrinolysis 2007;18:543-546.**

1083. Sacco R, Sacco M, Carpeneido M, Mannucci PM. Oral surgery in patients on oral anticoagulant therapy: A randomized comparison of different intensity targets.

**Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics 2007; 104: e18-21**

1084. Tedeschi A, Lorini M, Sulì C, Cugno M. Detection of serum histamine-releasing factors in a patient with idiopathic anaphylaxis and multiple drug allergy syndrome.

**Journal of Investigational Allergology and Clinical Immunology 2007;17:122-125.**

1085. Plate M, Asselta R, Peyvandi F, Tenchini ML, Duga S. Molecular characterization of the first missense mutation in the fibrinogen Aalpha-chain gene identified in a compound heterozygous afibrinogenemic patient.

**Biochimica et Biophysica Acta 2007; 1772: 781-787.**

1086. Radaelli F, Vener C, Ripamonti F, Iurlo A, Colombi M, Artoni A, Reda G, Deliliers GL. Conjunctival hemorrhagic events associated with imatinib mesylate.

**International Journal Hematology 2007;86:390-393**

1087. Franchini M, Tagliaferri A, Mannucci PM. The management of hemophilia in elderly patients.

**Clin Interv Aging 2007;2:361-368**

1088. Mannucci PM, Peyvandi F. TTP and ADAMTS13: When Is Testing Appropriate?

**Hematology 2007;2007:121-126**

1089. Gringeri A, Mannucci PM. Immunogenicity of factor VIII concen-

brates in patients with hemophilia: a randomized clinical trial is warranted.  
**Blood** 2007; 110:3084 (letter)

1090. Pengo V, Biasiolo A, Gresele P, Marongiu F, Erba N, Veschi F, Gherarduzzi A, Barcellona D, Tripodi A. A comparison of lupus anticoagulant-positive patients with clinical picture of antiphospholipid syndrome and those without.

**Arterioscler Thromb Vasc Biol.** 2007;27:e309-310. (letter)

1091. Tripodi A, Chantarangkul V. Performance of quantitative D-dimer methods: results of the Italian external quality assessment scheme.  
**Journal of Thrombosis and Haemostasis** 2007; 5: 184-185. (letter)

1092. Santagostino E. Can the genetic profile predict inhibitor development in hemophilia A?  
**Journal of Thrombosis and Haemostasis** 2007; 5: 261-262. (letter)

1093. Van den Besselaar AM, Tripodi A. Effect of daptomycin on prothrombin time and the requirement for outlier exclusion in International Sensitivity Index calibration of thromboplastin.

**Journal of Thrombosis and Haemostasis** 2007;5: 1975-1976 (letter)

1094. Pinol M, Sales M, Costa M, Tosetto A, Canciani MT, Federici AB. Evaluation of a new turbidimetric as-

say for von Willebrand factor activity useful in the general screening of von Willebrand disease.

**Haematologica** 2007;92:712-713. (letter)

1095. Asero R, Cugno M, Tedeschi A. Chronic urticaria: one step forward and two steps back.

**Journal of the American Academy of Dermatology** 2007;57:368-369. (letter)

1096. Mannucci PM. Polycythaemia vera and JAK2 mutation.

**Internal and Emergency Medicine**. 2007;2:147. (letter)

1097. Mannucci PM. Intracerebral haemorrhage and recombinant factor VIIa: not so good news!

**Internal and Emergency Medicine** 2007; 2: 235-236. (letter)

1098. Tripodi A. How to implement the modified international normalized ratio for cirrhosis (INR(liver)) for model for end-stage liver disease calculation.

**Hepatology** 2008;47:1423-1424

1099. Haberichter SL, Castaman G, Budde U, Peake I, Goodeve A, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill FG, Montgomery RR.

Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor (VWF) survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMMD-1VWD).

**Blood** 2008;111:4979-4985

1100. Castaman G, Lethagen S, Federici AB, Tosetto A, Goodeve A, Budde U, Batlle J, Meyer D, Mazurier C, Fressinaud E, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Pasi J, Hill F, Peake I, Rodeghiero F.

Response to desmopressin is influenced by the genotype and phenotype in type 1 Von Willebrand Disease (VWD): results from the European study MCMMD-1VWD.

**Blood** 2008;111:3531-3539

1101. Zhang B, Spreafico M, Zheng C, Yang A, Platzer P, Callaghan MU, Avci Z, Ozbek N, Mahlangu J, Haw T, Kaufman RJ, Marchant K, Tuddenham E, Seligsohn U, Peyvandi F, Ginsburg D. Genotype-phenotype correlation in combined deficiency of factor V and factor VIII.  
**Blood** 2008;111:5592-5600
1102. Bergamaschi GM, Primignani M, Barosi G, Fabris FM, Villani L, Reati R, Dell'Era A, Mannucci PM. MPL and JAK2 exon 12 mutations in patients with the Budd-Chiari syndrome or extrahepatic portal vein obstruction.  
**Blood** 2008;111:4418
1103. Martinelli I, Franchini M, Mannucci PM. How I treat rare venous thromboses.  
**Blood** 2008
1104. Federici AB, Mannucci PM, Castaman G, Baronciani L, Bucchiarelli P, Canciani MT, Pecci A, Lenting PJ, De Groot PG. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: A cohort study of 67 patients.  
**Blood** 2008
1105. Baccarelli A, Martinelli I, Zanobetti A, Grillo P, Hou LF, Bertazzi PA, Mannucci PM, Schwartz J. Exposure to particulate air pollution and risk of deep vein thrombosis.  
**Journal of Thrombosis and Haemostasis** 2008;6:494-498
1106. Asero R, Tedeschi A, Riboldi P, Griffini S, Bonanni E, Cugno M. Severe chronic urticaria is associated with elevated plasma levels of D-dimer.  
**Allergy** 2008;63:176-180
1107. Federici AB. Acquired von Willebrand syndrome: is it an extremely rare disorder or do we see only the tip of the iceberg?  
**Journal of Thrombosis and Haemostasis** 2008;6:565-568
1108. Tripodi A, Chantarangkul V, Mannucci PM. The international normalized ratio to prioritize patients for liver transplantation: problems and possible solutions.  
**Journal of Thrombosis and Haemostasis** 2008;6:243-248
1109. Martinelli I, Battaglioli T, De Stefano V, Tormene D, Valdrè L, Grandone E, Tosetto A, Mannucci PM; GIT (Gruppo Italiano Trombofilia). The risk of first venous thromboembolism during pregnancy and puerperium in double heterozygotes for factor V Leiden and prothrombin G20210A.  
**Journal of Thrombosis and Haemostasis** 2008;6:920-927
1110. Baronciani L, Federici AB, Castaman G, Punzo M, Manucci PM. Prevalence of type 2B "Malmö/New York" von Willebrand disease in Italy: the role of VWF gene conversion.  
**Journal of Thrombosis and Haemostasis** 2008; 6:887-890
1111. Budde U, Schneppenheim R, Eikenboom J, Goodeve A, Will K, Drewke E, Castaman G, Rodeghiero F, Federici AB, Batlle J, Pérez A, Meyer D, Mazurier C, Goudemand J, Ingleslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J, Hill F, Peake I. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD).  
**Journal of Thrombosis and Haemostasis** 2008;6:762-771
1112. Poller L, Keown M, Ibrahim S, Lowe G, Moia M, Turpie AG, Roberts C, van den Besselaar AM, van der Meer FJ, Tripodi A, Palareti G, Shiach C, Bryan S, Samama M, Burgess-Wilson M, Heagerty A, MacCallum P, Wright D, Jespersen J. An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage.  
**Journal of Thrombosis and Haemostasis** 2008;6:1042-1043
1113. Van den Besselaar AM, Hubbard AR, Tripodi A. Continuation of the international standard thromboplastin (human, recombinant, plain) by means of a replacement reconstitution fluid.  
**Journal of Thrombosis and Haemostasis** 2008;6:1049-1050
1114. Tripodi A. More on: criteria to define the antiphospholipid syndrome.  
**Journal of Thrombosis and Haemostasis** 2008;6:1450-1452
1115. Mannucci PM, Spreafico M, Peyvandi F. Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? No.  
**Journal of Thrombosis and Haemostasis** 2008;6: 1726-1728
1116. Federici AB. Clinical and molecular markers of inherited von Willebrand disease type 3: are deletions of the VWF gene associated with alloantibodies to VWF.  
**Journal of Thrombosis and Haemostasis** 2008;6: 1726-1728
1117. Tripodi A, Peyvandi F, Chantarangkul V, Palla R, Afrasiabi A, Canciani MT, Chung DW, Ferrari S, Fujimura Y, Karimi M, Kokame K, Kremer Hovinga JA, Lämmle B, De Meyer SF, Plaimauer B, Vanhoorebeke K, Varadi K, Mannucci PM. Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease

(ADAMTS-13).

**Journal of Thrombosis and Haemostasis 2008;6: 1534-1541**

1118. Tripodi A, Legnani C, Chantarangkul V, Cosmi B, Palareti G, Mannucci PM. High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism.

**Journal of Thrombosis and Haemostasis 2008;6:1327-1333**

1119. Blanchette VS, Shapiro AD, Liesner RJ, Hernández Navarro F, Warrier I, Schroth PC, Spotts G, Ewenstein BM; rAHF-PFM Clinical Study Group (Collaborators ... Gringeri A...). Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. **Journal of Thrombosis and Haemostasis 2008;6:1319-26**

1120. Colucci M, Cattaneo M, Martinelli I, Semeraro F, Binetti BM, Semeraro N. Mild hyperhomocysteinemia is associated with increased TAFI levels and reduced plasma fibrinolytic potential.

**Journal of Thrombosis and Haemostasis 2008;6.1571-1577**

1121. Gomperts ED, Astermark J, Gringeri A, Teitel J. From theory to practice: applying current clinical knowledge and treatment strategies

to the care of hemophilia a patients with inhibitors.

**Blood Review 2008;22 (S1):S1-11**

1122. Ingegnoli F, Fantini F, Favalli EG, Soldi A, Griffini S, Galbiati V, Meroni PL, Cugno M. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: Effects of tumor necrosis factor-alpha blockade.

**Journal of Autoimmunity 2008; 31: 175-179**

1123. Primignani M, Mannucci PM. The role of thrombophilia in splanchnic vein thrombosis.

**Seminars in Liver Disease 2008;28: 293-301**

1124. Peyvandi F, Lavoretano S, Palla R, Feys HB, Vanhoorelbeke K, Battaglioli T, Valsecchi C, Canciani MT, Fabris F, Zver S, Réti M, Mikovic D, Karimi M, Giuffrida G, Laurenti L, Mannucci PM. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.

**Haematologica 2008;93:232-239**

1125. Imberti D, Agnelli G, Ageño W, Moia M, Palareti G, Pistelli R, Rossi R, Verso M; MASTER Investigators. Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry.

**Haematologica 2008;93:273-278**

1126. Franchini M, Mannucci PM. Interactions between genotype and phenotype in bleeding and thrombosis.

**Haematologica. 2008;93:649-652**

1127. Legnani C, Palareti G, Cosmi B, Cini M, Tosetto A, Tripodi A; PROLONG Investigators (FCSA and Italian Federation of Thrombosis Centers). Different cut-off values of quantitative D-dimer methods to predict the risk of venous thromboembolism recurrence: a post-hoc analysis of the PROLONG study.

**Haematologica 2008;93:900-977**

1128. Tripodi A, Ramenghi LA, Chantarangkul V, De Carli A, Clerici M, Groppo M, Mosca F, Mannucci PM. Normal thrombin generation in neonates in spite of prolonged conventional coagulation tests.

**Haematologica 2008;93:1256-1259**

1129. Zadra G, Asselta R, Tenchini ML, Castaman G, Seligsohn U, Mannucci PM, Duga S. Simultaneous genotyping of coagulation factor XI type II and type III mutations by multiplex real-time polymerase chain reaction to determine their prevalence in healthy and factor XI-deficient Italians. **Haematologica 2008;93:715-721.**

1130. Zadra G, Asselta R, Ten-

chini ML, Castaman G, Seligsohn U, Mannucci PM, Duga S. Reply to: Factor XI mutation and the origin of Ashkenazi Jews.

**Haematologica 2008; 93:e59**

1131. Margaglione M, Castaman G, Morfini M, Rocino A, Santagostino E, Tagariello G, Tagliaferri AR, Zanon E, Bicocchi MP, Castaldo G, Peyvandi F, Santacroce R, Torricelli F, Grandone E, Mannucci PM; AICE-Genetics Study Group.

The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype.

**Haematologica,93:722-728 2008**

1132. Karimi M, Menegatti M, Afrasiabi A, Sarikhani S, Peyvandi F. Phenotype and genotype report on homozygous and heterozygous patients with congenital Factor X deficiency.

**Haematologica 2008,93.934-938**

1133. Franchini M, Peyvandi F, Mannucci PM. The genetic basis of coronary artery disease: from candidate genes to whole genome analysis. **Trends in Cardiovascular Medicine 2008;18):157-162**

1134. Di Stasio E, Lancellotti S, Peyvandi F, Palla R, Mannucci PM, De Cristofaro R. Mechanistic studies on ADAMTS13 catalysis.

**Biophysical Journal 2008;95:2450-2461**

1135. Mancuso ME, Mannucci PM, Sartori A, Agliardi A, Santagostino E. Feasibility of prophylaxis and immune tolerance induction regimens in haemophilic children using fully implantable central venous catheters.

**British Journal of Haematology**  
**2008;141:689-695**

1136. Poller L, Keown M, Ibrahim S, Lowe G, Moia M, Turpie AG, Roberts C, van den Besselaar AM, van der Meer FJ, Tripodi A, Palareti G, Jespersen J. A multicentre randomised clinical endpoint study of parma 5 computer-assisted oral anticoagulant dosage.

**British Journal of Haematology**  
**2008; 143:274-283**

1137. Rodger MA, Paidas M, Claire M, Middeldorp S, Kahn S, Martinelli I, Hague W, Rosene Montella K, Greer I. inherited thrombophilia and pregnancy complications revisited.

**Obstetric and Gynecology** 2008;  
**112(2 Pt 1):320-324**

1138. Beretta L, Cossu M, Marchini M, Cappiello F, Artoni A, Motta G, Scorza R. A polymorphism in the human serotonin 5-HT2A receptor gene may protect against systemic sclerosis by reducing platelet aggregation.

**Arthritis Research and Therapy**  
**2008;10:R103**

1139. Mannucci PM, Peyvandi F. Thrombophilia screening: little role for the JAK2V617F mutation.  
**Mayo Clin Proc** 2008;83:398-399

1140. Spreafico M, Lodigiani C, van Leeuwen Y, Pizzotti D, Rota LL, Rosendaal F, Mannucci PM, Peyvandi F. Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy.  
**Pharmacogenomics** 2008;9:1237-1250

1141. Tripodi A. Laboratory testing for lupus anticoagulants: diagnostic criteria and use of screening, mixing, and confirmatory studies.  
**Seminars in Thrombosis and Hemostasis** 2008;34:373-379

1142. Marzano AV, Tedeschi A, Fanoni D, Bonanni E, Venegoni L, Berti E, Cugno M. Activation of blood coagulation in bullous pemphigoid: role of eosinophils, and local and systemic implications.  
**British Journal of Dermatology**  
2008; 160:266-272

1143. Cazzaniga M, Salerno F, Visentin S, Cirello I, Donarini C, Cugno M. Increased flow-mediated vasodilation in cirrhotic patients with ascites: relationship with renal resistive index.  
**Liver International** 2008; 28:

### 1396-1401

1144. Platè M, Asselta R, Spena S, Spreafico M, Fagoonee S, Peyvandi F, Tenchini ML, Duga S. Congenital hypofibrinogenemia: Characterization of two missense mutations affecting fibrinogen assembly and secretion.  
**Blood Cells Molecular Disease** 2008; 41:292-297

1145. Santacroce R, Acquila M, Belvini D, Castaldo G, Garagiola I, Giacomelli SH, Lombardi AM, Minuti B, Riccardi F, Salvato R, Tagliabue L, Grandone E, Margaglione M; AICE-Genetics Study Group. Identification of 217 unreported mutations in the F8 gene in a group of 1,410 unselected Italian patients with hemophilia A.

**Journal of Human Genetic** 2008;53: 275-284

1146. Berntorp E, Archey W, Auerswald G, Federici AB, Franchini M, Knaub S, Kreuz W, Lethagen S, Mannucci PM, Pollmann H, Scharrer I, Hoots K. A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance.  
**European Journal of Haematology Suppl.** 2008;70:3-35

1147. Cugno M, Marzano AV, Tedeschi A, Fanoni D, Venegoni L, Asero R. Expression of Tissue Factor by Eosinophils in Patients with Chro-

nic Urticaria.

**International Archives of Allergy and Immunology** 2008;148:170-174

1148. Pan A, Testa S, Roldan EQ, Tinelli C, Bodini U, Cadeo B, Carnavale G, Martinelli I, Maserati R, Morstabilini P, Seminari E, Signorini L, Carosi G. Haemostatic activation in HIV infected patients treated with different antiretroviral regimens.  
**Current HIV Research** 2008;6: 70-76.

1149. Colvin BT, Astermark J, Fischer K, Gringeri A, Lassila R, Schramm W, Thomas A, Ingerslev J; Inter Disciplinary Working Group. European principles of haemophilia care.

**Haemophilia** 2008;14:361-374

1150. Federici AB, Mannucci PM, Marco P. Von Willebrand factor in high-purity factor VIII complex concentrates: chaperone protein or key to therapies? A meeting report.  
**Haemophilia** 2008;14:133-139

1151. Nicholson A, Berger K, Bohn R, Carcao M, Fischer K, Gringeri A, Hoots K, Mantovani L, Schramm W, van Hout BA, Willan AR, Feldman BM. Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert

Working Group of The International Prophylaxis Study Group.  
**Haemophilia** 2008;14:127-132.

1152. Maino A, Garagiola I, Artoni A, Al-Humood S, Peyvandi F. A novel mutation of alpha2-plasmin inhibitor gene causes an inherited deficiency and a bleeding tendency.  
**Haemophilia** 2008;14:166

1153. Mannucci PM. Desmopressin: an historical introduction.  
**Haemophilia** 2008;14 (S1) 1:1-4

1154. Federici AB. The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007).  
**Haemophilia** 2008;14 (S1):5-14

1155. Mannucci PM. Back to the future: a recent history of hemophilia treatment.  
**Haemophilia** 2008;14 (s3):10-18

1156. Collins P, Budde U, Rand JH, Federici AB, Kessler CM. Epidemiology and general guidelines of the management of acquired haemophilia and von Willebrand syndrome.  
**Haemophilia** 2008;14 (S3):49-55

1157. Baronciani L, Federici AB, Cozzi G, La Marca S, Punzo M, Rubini V, Canciani MT, Mannucci PM. Expression studies of missense mutations p.D141Y, p.C275S located in the propeptide of von Willebrand

factor in patients with type 3 von Willebrand disease.  
**Haemophilia** 2008;14:549-555.

1158. Feldman BM, Funk S, Lundin B, Doria AS, Ljung R, Blanchette V; International Prophylaxis Study Group (IPSG) [collaborators] ... Gringeri A...]. Musculoskeletal measurement tools from the International Prophylaxis Study Group (IPSG).  
**Haemophilia** 2008;14 (S3):162-169

1159. Gringeri A, von Mackensen S. Quality of life in hemophilia.  
**Haemophilia** 2008; 14 (S3): 19-25

1160. Peyvandi F, Cattaneo M, Inbal A, De Moerloose P, Spreafico M. Rare bleeding disorders.  
**Haemophilia** 2008;14 (S3):202-210

1161. Tuddenham EG, Ingerslev J, Sørensen LN, Christiansen K, Mariani G, Peyvandi F, Waddington SN, Buckley SM, Kochanek S, Chuah MK, Vandendriessche T, Berntorp E. Genetic aspects and research development in haemostasis.  
**Haemophilia** 2008;14 (S3):113-118

1162. Tagliaferri A, Franchini M, Coppola A, Rivolta GF, Santoro C, Rossetti G, Feola G, Zanon E, Dragani A, Iannaccaro P, Radossi P, Mannucci PM. Effects of secondary pro-

phylaxis started in adolescent and adult haemophiliacs.  
**Haemophilia** 2008;14:945-951.

1163. Franchini M, Gandini G, Giuffrida A, De Gironcoli M, Federici AB. Treatment for patients with type 3 von Willebrand disease and alloantibodies: a case report.  
**Haemophilia** 2008; 14:645-646

1164. Iorio A, Oliovecchio E, Morfini M, Mannucci PM; The Association Of Italian Hemophilia Centres Directors (collaborators... Santagostino E, Gringeri A, Federici AB...). Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis.  
**Haemophilia** 2008;14:444-453

1165. Palareti G, Agnelli G, Imberti D, Moia M, Ageno W, Pistelli R, Rossi R, Verso M; MASTER investigators. A commentary: to screen for calf DVT or not to screen? The highly variable practice among Italian centers highlights this important and still unresolved clinical option. Results from the Italian MASTER registry.  
**Thrombosis and Haemostasis** 2008; 99:241-244

1166. Musso R, Santagostino E, Faradji A, Iorio A, van der Meer J, Ingerslev J, Lambert T, Maas-Enriquez M, Gorina E; KOGENATE Bayer European PMS Study Group. Safety and efficacy of sucrose-for-

mulated full-length recombinant factor VIII: experience in the standard clinical setting.  
**Thrombosis and Haemostasis** 2008; 99:52-58

1167. Agnelli G, Verso M, Ageno W, Imberti D, Moia M, Palareti G, Rossi R, Pistelli R; for the MASTER investigators. The MASTER registry on venous thromboembolism: Description of the study cohort.  
**Thrombosis Research** 2008;121: 605-610

1168. Ageno W, Agnelli G, Imberti D, Moia M, Palareti G, Pistelli R, Rossi R, Verso M; for the MASTER Investigators. Factors associated with the timing of diagnosis of venous thromboembolism: Results from the MASTER registry.  
**Thrombosis Research** 2008;121: 751-756

1169. Asero R, Tedeschi A, Riboldi P, Griffini S, Bonanni E, Cugno M. Coagulation cascade and fibrinolysis in patients with multiple-drug allergy syndrome.  
**Annals of Allergy, Asthma and Immunology** 2008;100:44-48

1170. Primignani M, Dell'Era A, Bucciarelli P, Bottasso B, Bajetta MT, de Franchis R, Cattaneo M. High-d-dimer plasma levels predict poor outcome in esophageal variceal bleeding.

**Digestive and Liver Disease 2008; 40: 874-881**

1171. Afrasiabi A, Gelain F, Artoni A, Mannucci PM. AlphallbG236E causes Glanzmann thrombasthenia by impairing association with beta3. **Platelets 2008;19:322-327**

1172. Khalife H, Muwakkit S, Al-Moussawi H, Dabbous I, Khoury R, Peyvandi F, Abboud MR. Spontaneous splenic rupture in a patient with factor XIII deficiency and a novel mutation.

**Pediatric Blood Cancer 2008;50: 113-114**

1173. Ageno W, Agnelli G, Imberti D, Moia M, Palareti G, Pistelli R, Rossi R, Verso M; MASTER Investigators. Risk factors for venous thromboembolism in the elderly: results of the Master registry.

**Blood Coagulation and Fibrinolysis 2008;19:663-667**

1174. Mannucci PM. Autoimmune hemophilia.

**Blood Transfusion 2008;6:6-7**

1175. Iapichino G, Albicini M, Umbrello M, Sacconi F, Fermo I, Pavlovich R, Paroni R, Bellani G, Mistraletti G, Cugno M, Pesenti A, Gattinoni L. Tight glycemic control does not affect asymmetric-dimethylarginine in septic patients.

**Intensive Care Med. 2008; 34:**

**1843-1850**

1176. Franchini M, Mannucci PM. Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura. **Blood Transfusion 2008;6:127-35.**

1177. Franchini M, Mannucci PM. The hemostatic balance revisited through the lessons of mankind evolution.

**Internal and Emergency Medicine 2008; 3:3-8**

1178. Federici AB. Update on the management of von Willebrand disease.

**Clinical Advances in Hematology and Oncology 2008;6:29-30**

1179. Bullinger M, Gringeri A, von Mackensen S. [Quality of life of young patients with haemophilia in Europe] **Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2008;51:637-645**

1180. Tripodi A. Hemostasis abnormalities in liver cirrhosis: myth or reality?

**Pol Arch Med Wewn. 2008;118: 445-448**

1181. Mannucci PM, Spreafico M, Peyvandi F. Genetics of warfarin response.

**New England Journal of Medicine 2008;358:2743 (letter)**

1182. Tripodi A, Mannucci PM. Reply to: Endogenous heparinoids con tribute to coagulopathy in patients with liver disease.

**Journal of Hepatology 2008;48: 372-373 (letter).**

1183. Asero R, Cugno M, Tedeschi A. Chronic idiopathic urticaria: what is the meaning of skin reactivity to autologous serum?

**Journal of the European Academy of Dermatology and Venereology 2008;22: 135-136 (letter)**

1184. Goedert JJ, Scoppio BM, Pfeiffer R, Neve L, Federici AB, Long LR, Dolan BM, Brambati M, Bellinvia M, Lauria C, Preiss L, Boneschi V, Whitby D, Brambilla L. Treatment of classic Kaposi sarcoma with a nicotine dermal patch: a phase II clinical trial.

**Journal of the European Academy of Dermatology and Venereology 2008;22:1101-1109. (letter)**

1185. Peyvandi F, Lotta LA, Mannucci PM. Inhibitors of factor VIII in hemophilia.  
**New England Journal of Medicine** 2009;361:309
1186. Myocardial Infarction Genetics Consortium\* (Kathiresan S, Voight BF, Purcell S, Musunuru K, Ardissino D, Mannucci PM, Peyvandi F, et al). Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants.  
**Nature Genetics** 2009;41:334-341.
1187. Erdmann J, Großhennig A, Braund PS, König IR, Hengstenberg C, Hall AS, Linsel-Nitschke P, Kathiresan S, Wright B, Trégouët DA, Cambien F, Bruse P, Aherrahrou Z, Wagner AK, Stark K, Schwartz SM, Salomaa V, Elosua R, Melander O, Voight BF, O'Donnell CJ, Peltonen L, Siscovick DS, Altshuler D, Merlini PA, Peyvandi F, Bernardinelli L, Ardissino D, Schillert A, Blankenberg S, Zeller T, Wild P, Schwarz DF, Tiret L, Perret C, Schreiber S, Mokhtari NE, Schäffer A, März W, Renner W, Bugert P, Klüter H, Schrezenmeir J, Rubin D, Ball SG, Balmforth AJ, Wichmann HE, Meitinger T, Fischer M, Meisinger C, Baumert J, Peters A, Ouwendahl WH; Italian Atherosclerosis, Thrombosis, and Vascular Biology Working Group; Myocardial Infarction Genetics Consortium; Wellcome Trust Case Control Consortium; Cardiogenics Consortium, Deloukas P, Thompson JR, Ziegler A, Samani NJ, Schunkert H. New susceptibility locus for coronary artery disease on chromosome 3q22.3.  
**Nature Genetics** 2009;41:280-282.
1188. Baccarelli A, Martinelli I, Pegoraro V, Melly S, Grillo P, Zanobetti A, Hou L, Bertazzi PA, Mannucci PM, Schwartz J. Living Near Major Traffic Roads and Risk of Deep Vein Thrombosis.  
**Circulation** 2009;119:3118-3124
1189. Pengo V, Cucchini U, Denas G, Erba N, Guazzaloca G, La Rosa L, De Micheli V, Testa S, Frontoni R, Prisco D, Nante G, Iliceto S; Italian Federation of Centers for the Diagnosis of Thrombosis and Management of Antithrombotic Therapies (FCSA) (Appendix ... Moia M, Oliviero B....). Standardized low-molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study.  
**Circulation** 2009;119:2920-2927
1190. Tripodi A, Primignani M, Chantarangkul V, Dell'era A, Clerici M, de Franchis R, Colombo M, Mannucci PM. An Imbalance of Pro-vs Anti-Coagulation Factors in Plasma from Patients with Cirrhosis.
1191. Federici AB, Mannucci PM, Castaman G, Baronciani L, Buccarella P, Canciani MT, Pecci A, Lenting PJ, De Groot PG. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients.  
**Blood** 2009;113:526-534
1192. Tagariello G, Iorio A, Santagostino E, Morfini M, Bisson R, Innocenti M, Mancuso ME, Mazzucconi MG, Pasta GL, Radossi P, Rodorigo G, Santoro C, Sartori R, Scaraggi A, Solimeno LP, Mannucci PM. Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the two coagulation disorders.  
**Blood** 2009; 114:779-784
1193. Mannucci PM, Schutgens RE, Santagostino E, Mauser-Bunschoten EP. How I treat age-related morbidities in elderly persons with hemophilia.  
**Blood** 2009; 114:5256-5263
1194. Asero R, Tedeschi A, Cugno M. Is the autologous plasma skin test in patients with chronic urticaria really useless? Reply.  
**Journal of Allergy Clinical Immunology** 2009; 123: 1417-1418
1195. Cugno M, Zanichelli A, Foieni F, Caccia S, Cicardi M. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress.  
**Trends in Molecular Medicine** 2009; 15:69-78
1196. Cugno M, Borghi MO, Lonati LM, Ghiadoni L, Gerosa M, Grossi C, De Angelis V, Magnaghi G, Tincani A, Mari D, Riboldi P, Meroni PL. Patients with antiphospholipid syndrome display endothelial perturbation.  
**J Autoimmun**. 2009; 34:105-110
1197. Martinelli I, Primignani M, Aghemo A, Reati R, Bucciarelli P, Fabris F, Battaglioli T, Dell'Era A, Mannucci PM. High levels of factor VIII and risk of extra-hepatic portal vein obstruction.  
**Journal of Hepatology** 2009;50: 916-922
1198. Tripodi A, Chantarangkul V, Primignani M, Dell'Era A, Clerici M, Iannuzzi F, Aghemo A, Cazzaniga M, Salerno F, Mannucci PM. Point-of-care coagulation monitors calibrated for the international normalized ratio for cirrhosis (INR(liver)) can help to implement the INR(liver) for the calculation of the MELD score.  
**Journal of Hepatology** 2009;51: 288-295
1199. Lotta LA, Garagiola I, Palla R, Cairo A, Peyvandi F. ADAMTS13

mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura.

**Human Mutation 2010; 31:11-19**

1200. Savioli M, Cugno M, Polli F, Taccone P, Bellani G, Spanu P, Pesenti A, Iapichino G, Gattinoni L. Tight glycemic control may favor fibrinolysis in patients with sepsis\*. **Critical Care Medicine 2009; 37:424-431**

1201. Siboni SM, Mannucci PM, Gringeri A, Franchini M, Tagliaferri A, Ferretti M, Tradati FC, Santagostino E, von Mackensen S; for the Italian Association of Haemophilia Centres (AICE). Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy. **Journal of Thrombosis and Haemostasis 2009;7:780-786**

1202. Collins PW, Blanchette VS, Fischer K, Björkman S, Oh M, Fritsch S, Schroth P, Spotts G, Astemark J, Ewenstein B; rAHF-PFM Study Group (in appendix ... Mannucci PM, Gringeri A ....). Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A.

**Journal of Thrombosis and Haemostasis 2009;7:413-420**

1203. Tripodi A, Legnani C, Palareti G, Chantarangkul V, Mannucci PM. More on: high thrombin generation and the risk of recurrent venous thromboembolism. **Journal of Thrombosis and Haemostasis 2009; 7: 906-907**

1204. Jowett S, Bryan S, Poller L, van den Besselaar AM, van der Meer FJ, Palareti G, Shiach C, Tripodi A, Keown M, Ibrahim S, Lowe G, Moia M, Turpie AG, Jespersen J. The cost-effectiveness of computer-assisted anticoagulant dosage: results from the European Action on Anticoagulation (EAA) multicentre study. **Journal of Thrombosis and Haemostasis. 2009;7:1482-1490**

1205. Bernardi F, Dolce A, Pinotti M, Shapiro AD, Santagostino E, Peyvandi F, Batorova A, Lapecorella M, Schved JF, Ingerslev J, Mariani G; for the International Factor VII Deficiency Study Group. Major differences in bleeding symptoms between factor VII deficiency and hemophilia B. **Journal of Thrombosis and Haemostasis 2009;17:774-779**

1206. Baronciani L, Federici AB, Punzo M, Solimando M, Cozzi G, La Marca S, Rubini V, Canciani MT, Mannucci PM. TYPE 2A (IIH) von Willebrand disease is due to mutations that affect von Willebrand factor multimerization. **Journal of Thrombosis and Haemo-**

**stasis 2009; 7: 1114-1122**

1207. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, De Groot PG. Update of the guidelines for lupus anticoagulant detection. **Journal of Thrombosis and Haemostasis 2009; 7:1737-1740**

1208. Coppola A, Margaglione M, Santagostino E, Rocino A, Grandone E, Mannucci PM, Di Minno G; for the AICE PROFIT Study Group\*\*. Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction (ITI) of hemophilia A patients with high-responding inhibitors. **Journal of Thrombosis and Haemostasis 2009; 7:1809 -1815**

1209. Castaman G, Mancuso ME, Giacomelli SH, Tosetto A, Santagostino E, Mannucci PM, Rodeghiero F. Molecular and phenotypic determinants of response to desmopressin in adult patients with mild hemophilia A. **Journal of Thrombosis and Haemostasis 2009 Aug 28. [Epub ahead of print]**

1210. Nurden AT, Federici AB, Nurden P. Altered megakaryocytopoiesis in von Willebrand type 2B disease. **Journal of Thrombosis and Haemostasis 2009; 7 (S1):277-81**

1211. Eikenboom J, Hilbert L, Ribba AS, Hommais A, Habart D, Messenger S, Al-Buhairan A, Guillatt A, Lester W, Mazurier C, Meyer D,

Fressinaud E, Budde U, Will K, Schneppenheim R, Obser T, Marggraf O, Eckert E, Castaman G, Rodeghiero F, Federici AB, Batlle J, Goudemand J, Ingerslev J, Lethagen S, Hill F, Peake I, Goodeve A. Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study. **Journal of Thrombosis and Haemostasis 2009;7:1304-1312**

1212. Mancuso ME, Rumi MG, Aghemo A, Santagostino E, Puoti M, Coppola A, Colombo M, Mannucci PM. HCV/HIV co-infection in hemophiliacs: high rates of sustained virological response to pegylated interferon and ribavirin therapy. **Journal of Thrombosis and Haemostasis 2009; 7: 1997- 2005**

1213. Poller L, Roberts C, Ibrahim S, Keown M, Ageno W, Van Den Besselaar AM, Fitzmaurice D, Harenberg J, Kitchen S, Lowe G, Moia M, Palareti G, Tripodi A, Turpie AG, Jespersen J; Subcommittee on Control of Anticoagulation of the SSC of the ISTH. Screening computer-assisted dosage programs for anticoagulation with warfarin and other vitamin K antagonists: minimum safety requirements for individual programs. **Journal of Thrombosis and Haemostasis 2009;7:1736 (letter).**

1214. Manco-Johnson MJ, Dimi-

chele D, Castaman G, Fremann S, Knaub S, Kalina U, Peyvandi F, Piseddu G; Mannucci PM for the Fibrinogen Concentrate Study Group. Pharmacokinetics and safety of fibrinogen concentrate.

**Journal of Thrombosis and Haemostasis 2009; 7: 2064 - 2069**

1215. Cugno M, Zanichelli A, Bel-latorre AG, Griffini S, Cicardi M. Plasma biomarkers of acute attacks in patients with angioedema due to C1-inhibitor deficiency.

**Allergy 2009;64:254-257**

1216. Tedeschi A, Asero R, Marzano AV, Lorini M, Fanoni D, Berti E, Cugno M. Plasma levels and skin-eosinophil-expression of vascular endothelial growth factor in patients with chronic urticaria.

**Allergy 2009;64:1616-1622**

1217. Palla R, Lavoretano S, Lombardi R, Garagiola I, Karimi M, Afrasiabi A, Ramzi M, De Cristofaro R, Peyvandi F. The first deletion mutation in the TSP1-6 repeat domain of ADAMTS13 in a family with inherited thrombotic thrombocytopenic purpura.

**Haematologica. 2009;94:289-293**

1218. Mannucci PM, Peyvandi F. Autoimmune hemophilia at rescue.

**Haematologica 2009; 94:459-461**

1219. Federici AB, Canciani MT. Clinical and laboratory versus mole-

cular markers for a correct classification of von Willebrand disease.

**Haematologica 2009; 94:610-615**

1220. Mancuso ME, Berardinelli L, Beretta C, Raiteri M, Pozzoli E, Santagostino E. Improved treatment feasibility in children with hemophilia using arteriovenous fistulae: the results after seven years of follow-up.

**Haematologica 2009 Mar 13**

1221. Plate' M, Duga S, Baronciani L, La Marca S, Rubini V, Mannucci PM, Federici AB, Asselta R. Premature termination codon mutations in the Von Willebrand factor gene are associated with allele-specific and position-dependent mRNA decay.

**Haematologica 2009; 95: 172 - 174**

1222. Tripodi A, Cappellini MD, Chantarangkul V, Padovan L, Fasullo MR, Marcon A, Mannucci PM. Hypercoagulability in splenectomized thalassemic patients detected by whole-blood thromboelastometry, but not by thrombin generation in platelet-poor plasma.

**Haematologica 2009; 94:1520-1527**

1223. Nurden P, Nurden AT, La Marca S, Punzo M, Baronciani L, Federici AB. Platelet morphological changes in two patients with von Willebrand disease type 3 caused by large homozygous deletions of the von Willebrand factor gene.

**Haematologica 2009; 94: 1627 - 1629**

1224. Solimeno LP, Mancuso ME, Pasta G, Santagostino E, Perfetto S, Mannucci PM. Factors influencing the long-term outcome of primary total knee replacement in haemophiliacs: a review of 116 procedures at a single institution.

**British Journal of Haematology 2009; 145: 227-234**

1225. Biguzzi E, Mancuso P, Franchi F, Calleri A, Mancuso ME, Santagostino E, Bucciarelli P, Bertolini F, Mannucci PM. Circulating endothelial cells (CECs) and progenitors (CEPs) in severe haemophiliacs with different clinical phenotype.

**British Journal of Haematology 2009;144:803-805**

1226. Tripodi A, Chantarangkul V, Mannucci PM. Acquired coagulation disorders: revisited using global coagulation/anticoagulation testing.

**British Journal of Haematology 2009; 147:77-82**

1227. Peyvandi F, Palla R, Mengatti M, Mannucci PM. Introduction. Rare bleeding disorders: general aspects of clinical features, diagnosis, and management.

**Seminars in Thrombosis and Hemostasis 2009;35:349-355**

1228. Marzano AV, Tedeschi A, Fanoni D, Bonanni E, Venegoni L, Berti E, Cugno M. Activation of blood

coagulation in bullous pemphigoid: role of eosinophils, and local and systemic implications.

**British Journal of Dermatology 2009;160:266-272**

1229. Taliani MR, Becattini C, Agnelli G, Prandoni P, Moia M, Bazan M, Salvi R, Ageno W, Guazzaloca G, Imberti D, Silingardi M, Poggio R; for the Warfarin Optimal Duration Italian Trial (WODIT) Investigators. Duration of anticoagulant treatment and recurrence of venous thromboembolism in patients with and without thrombophilic abnormalities.

**Thrombosis and Haemostasis 2009;101:596-598**

1230. Poller L, Keown M, Ibrahim S, Lowe G, Moia M, Turpie AG, Roberts C, van den Besselaar AM, van der Meer FJ, Tripodi A, Palareti G, Shiach C, Bryan S, Samama M, Burgess-Wilson M, Heagerty A, MacCallum P, Wright D, Jespersen J; European Action on Anticoagulation (EAA). A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program.

**Thrombosis and Haemostasis 2009 Mar;101(3):487-494.**

1231. Spena S, Asselta R, Caccia S, Rimoldi V, Giacomelli SH, Tagliaferri A, Peyvandi F, Castaman G, Duga S. Analysis of the structural effects of four novel and a previously

known mutations causing factor XI deficiency.

**Thrombosis and Haemostasis 2009;102:603-606**

1232. Tripodi A, van den Bessehaar A. Laboratory monitoring of anti-coagulation: where do we stand?

**Seminars in Thrombosis and Hemostasis 2009;35:34-41**

1233. Menegatti M, Peyvandi F. Factor X deficiency.

**Seminars in Thrombosis and Hemostasis 2009;35:407-415**

1234. Spreafico M, Peyvandi F. Combined Factor V and Factor VIII Deficiency.

**Seminars in Thrombosis and Hemostasis 2009;35:390-399**

1235. Asselta R, Peyvandi F. Factor V deficiency.

**Seminars in Thrombosis and Hemostasis 2009;35:382-389**

1236. Peyvandi F, Favaloro EJ. Rare bleeding disorders.

**Seminars in Thrombosis and Hemostasis 2009;35:345-347**

1237. James AH, Kouides PA, Abdul-Kadir R, Edlund M, Federici AB, Halimeh S, Kamphuisen PW, Konkle BA, Martínez-Perez O, McLintock C, Peyvandi F, Winikoff R. Von Willebrand disease and other bleeding disorders in women: Consensus

on diagnosis and management from an international expert panel.

**American Journal of Obstetrics and Gynecology 2009; 201: e1-8**

1238. Marzano AV, Tedeschi A, Spinelli D, Fanoni D, Crosti C, Cugno M. Coagulation activation in autoimmune bullous diseases.

**Clin Exp Immunol 2009; 158:31-36**

1239. Cugno M, Tedeschi A, Asero R, Meroni PL, Marzano AV. Skin autoimmunity and blood coagulation.

**Autoimmunity. 2010; 43: 189-194**

1240. Karimi M, Jafari H, Lahsaeizadeh S, Afrasiabi A, Akbari A, Dehbozorgian J, Ardeshiri R, Guella I, Asselta R, Peyvandi F. Factor XI deficiency in Southern Iran: identification of a novel missense mutation.

**Annals of Hematology 2009;88: 359-363**

1241. Tripodi A, Primignani M, Chantarangkul V, Viscardi Y, Dell'era A, Fabris FM, Mannucci PM. The coagulopathy of cirrhosis assessed by thromboelastometry and its correlation with conventional coagulation parameters.

**Thrombosis Research 2009; 124: 132-136**

1242. Cosmi B, Alatri A, Cattaneo M, Gresele P, Marietta M, Rodeghiero F, Tripodi A, Ansaldi L, Fusari M,

Taddei S. Assessment of the risk of bleeding in patients undergoing surgery or invasive procedures: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISTET).

**Thrombosis Research 2009;124: e 6-e12.**

1243. Martinelli I. WITHDRAWN: Counselling women about hormonal therapy.

**Thrombosis Research. 2009 [Epub ahead of print]**

1244. Martinelli I. Counselling women about hormonal therapy.

**Thrombosis Research 2009;123 (S2):S74-8.**

1245. Toulon P, Smirnov M, Triscott M, Safa O, Biguzzi E, Bouziane K, Tripodi A. A new chromogenic assay (HemosIL ThromboPath) is sensitive to major prothrombotic risk factors affecting the protein C pathway.

Results of a multicenter study.

**Thrombosis Research 2009; 124: 137-143**

1246. Lussana F, Dentali F, Abbate R, d'Aloja E, D'Angelo A, De Stefano V, Faioni EM, Grandone E, Legnani C, Martinelli I, Simioni P, Torrione D. Screening for thrombophilia and antithrombotic prophylaxis in pregnancy: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISTET).

**Thrombosis Research 2009; 124: e19-25**

1247. Mannucci PM, Palhares de Miranda PA. International survey of attitudes towards secondary prophylaxis with recombinant factor VIIa in haemophilia A patients with inhibitors.

**Haemophilia. 2009;15:345-347**

1248. Mancuso ME, Graca L, Auerswald G, Santagostino E. Haemophilia care in children—benefits of early prophylaxis for inhibitor prevention.

**Haemophilia. 2009;15(S1):8-14**

1249. Kaveri S, Gringeri A, Heissel-Kurth M, Kreuz W. Inhibitors in haemophilia A: the role of VWF/FVIII concentrates—a meeting report.

**Haemophilia 2009;15:587-591**

1250. Scalzone L, Mantovani LG, Borghetti F, Von Mackensen S, Gringeri A. Patients', physicians', and pharmacists' preferences towards coagulation factor concentrates to treat haemophilia with inhibitors: results from the COHIBA Study.

**Haemophilia 2009;15:473-486**

1251. Valentino LA, Carcao M, Mathew P, Leissinger CA, Berntorp E, Blanchette V, Escuriola-Eettinghausen C, Ewenstein B, Ewing N, Gringeri A, Hoots WK, Negrier C. The application of bypassing-agent

prophylaxis in haemophilia A patients with inhibitors: a meeting report.  
**Haemophilia** 2009; 15: 959 - 965

1252. Mannucci PM, Federici AB, James AH, Kessler CM. von Willebrand disease in the 21st century: current approaches and new challenges.  
**Haemophilia** 2009; 15:1154-1158

1253. Siboni SM, Spreafico M, Calò L, Maino A, Santagostino E, Federici AB, Peyvandi F. Gynaecological and obstetrical problems in women with different bleeding disorders.  
**Haemophilia**. 2009; 15: 1291-1299

1254. Federici AB, Barillari G, Zanon E, Mazzucconi MG, Musso R, Targhetta R, Mannucci PM. Efficacy and safety of highly purified, doubly virus-inactivated VWF/FVIII concentrates in inherited von Willebrand's disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score.  
**Haemophilia**. 2009; 16: 101-110

1255. Gringeri A. Bypassing agent regimens and costs for prophylaxis in patients with inhibitors.  
**Haemophilia**. 2009; 15: 1336-1337

1256. Santagostino E, Morfini M, Auerswald GK, Benson GM, Salek SZ, Lambert T, Salaj P, Jimenez-Yuste V, Ljung RC. Paediatric haemophilia

with inhibitors: existing management options, treatment gaps and unmet needs.

**Haemophilia** 2009;15:983-989

1257. Cosmi B, Legnani C, To-setto A, Pengo V, Ghirarduzzi A, Alatri A, Prisco D, Poli D, Tripodi A, Palareti G. Use of D-dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study.

**Journal of Thrombosis and Thrombolysis** 2009; 28: 381-388

1258. Tripodi A. Testing for lupus anticoagulants: all that a clinician should know.

**Lupus** 2009;18:291-8

1259. Cugno M, Marzano AV, Tedeschi A, Fanoni D, Venegoni L, Asero R. Expression of tissue factor by eosinophils in patients with chronic urticaria.

**Int Arch Allergy Immunol** 2009;148: 170-174

1260. Garcia D, Ageno W, Bussey H, Eikelboom J, Margaglione M, Marongiu F, Moia M, Palareti G, Pengo V, Poli D, Schulman S, Witt D, Wittkowsky A, Crowther M. Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Pre-

vention.  
**American Journal of Hematology** 2009;84:579-583

1261. Mannucci PM. [In Process Citation]

**European Journal of Internal Medicine** 2009;20:1

1262. Franchini M, Mannucci PM. A new era for anticoagulants.

**European Journal of Internal Medicine** 2009;20:562-568

1263. Mannucci PM, Franchini M, Castaman G, Federici AB; AICE (Italian Association of Haemophilia Centres) [Appendix ... A. Gringeri; E. Santagostino]. Evidence-based recommendations on the treatment of von Willebrand disease in Italy.

**Blood Transfusion** 2009; 7:117-26

1264. Tripodi A, Primignani M, Mannucci PM. Abnormalities of hemostasis and bleeding in chronic liver disease: the paradigm is challenged.  
**Internal and Emergency Medicine** 2010; 5: 7-12

1265. Ponticelli C, Moia M, Montagnino G. Renal allograft thrombosis.  
**Nephrol Dial Transplant**. 2009 Jan 31

1266. Tripodi A. Tests of coagulation in liver disease.

**Clinical Liver Disease** 2009;13:55-61

1267. Federici AB. The safety of

plasma-derived von Willebrand/factor VIII concentrates in the management of inherited von Willebrand disease.

**Expert Opin Drug Saf** 2009;8:203-210

1268. Bucciarelli P, Mannucci PM. The hemostatic system through aging and menopause.

**Climacteric**. 2009; 12 (S1):47-51

1269. Franchini M, Mannucci PM. Review: Multiple gene interaction and modulation of hemostatic balance.

**Clin Chem Lab Med** 2009; 47: 1455-1460

1270. Taban S, Fotouhi Ghiam A, Mosallaei A, Bordbar MR, Mannucci PM, Karimi M. Frequency of antiphospholipid antibodies in Iranian patients with solid malignancies: a pilot study.  
**Iran J Immunol** 2009;6:160-2

1271. Polli F, Savioli M, Cugno M, Taccone P, Bellani G, Spanu P, Pesenti A, Iapichino G, Gattinoni L. Effects of recombinant human activated protein C on the fibrinolytic system of patients undergoing conventional or tight glycemic control.  
**Minerva Anestesiol**. 2009;75:417-26.



1272 Martinelli I, Bucciarelli P, Passamonti SM, Battaglioli T, Previtali E, Mannucci PM.

Long-term evaluation of the risk of recurrence after cerebral sinus-venous thrombosis.

**Circulation** 2010; 121: 2740-2746

1273 Nurden P, Gobbi G, Nurden A, Enouf J, Youlyouz-Marfak I, Carubbi C, La Marca S, Punzo M, Baronciani L, De Marco L, Vitale M, Federici AB. Abnormal VWF modifies megakaryocytopoiesis: studies of platelets and megakaryocyte cultures from von Willebrand disease type 2B patients.

**Blood** 2010, 115:2649-2656

1274 Asselta R, Rimoldi V, Guella I, Soldà G, De Cristofaro R, Peyvandi F, Duga S. Molecular characterization of in-frame and out-of-frame alternative splicings in coagulation factor XI pre-mRNA.

**Blood** 2010;115:2065-2071

1275 Cosmi B, Legnani C, Tosetto A, Pengo V, Ghirarduzzi A, Testa S, Prisco D, Poli D, Tripodi A, Marongiu F, Palareti G; PROLONG Investigators ( on behalf of Italian Federation of Anticoagulation Clinics). Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism : the PROLONG II prospective study.

**Blood** 2010; 115:481-488

1276 Cugno M, Borghi MO, Lonati LM, Ghiadoni L, Gerosa M, Grossi C, De Angelis V, Magnaghi G, Tincani A, Mari D, Riboldi P, Meroni PL. Patients with antiphospholipid syndrome display endothelial perturbation.

**Journal of Autoimmunity** 2010; 34: 105-110

1277 Lotta LA, Garagiola I, Palla R, Cairo A, Peyvandi F. ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura.

**Human Mutation** 201; 31:11-19

1278 Porte RJ, Lisman T, Tripodi A, Caldwell SH, Trotter JF; Coagulation in Liver Disease Study Group. The International Normalized Ratio (INR) in the MELD score: problems and solutions.

**American Journal of Transplantation** 2010; 10: 1349-1353.

1279 Platè M, Duga S, Baronciani L, La Marca S, Rubini V, Mannucci PM, Federici AB, Asselta R. Premature termination codon mutations in the von Willebrand factor gene are associated with allele-specific and position-dependent mRNA decay.

**Haematologica** 2010; 95: 172-174

1280 Martinelli I, Bucciarelli P, Mannucci PM. Thrombotic risk factors: basic pathophysiology.

**Critical Care Medicine** 2010; 38 (2

#### SupplI :S3-9

1281 Lancellotti S, De Filippis V, Pozzi N, Peyvandi F, Palla R, Rocca B, Rutella S, Pitocco D, Mannucci PM, De Cristofaro R. Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13: A new prothrombotic mechanism in diseases associated with oxidative stress.

**Free Radical Biology and Medicine** 2010; 48 :446-456

1282 Björkman S, Blanchette VS, Fisher K, Oh M, Spotts G, Schroth P, Fritsch S, Patrone L, Ewenstein BM; Advate Clinical Program Group, Collins PW (.. Gringeri A, Mannucci PM...). Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring.

**Journal of Thrombosis and Haemostasis** 2010 ; 8:730-736

1283 Santagostino E, Mancuso ME, Tripodi A, Chantarangkul V, Clerici M, Garagiola I, Mannucci PM. Severe haemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile.

**Journal of Thrombosis and Haemostasis** 2010; 8; 737-743

- 1284 Bonzini M, Tripodi A, Artoni A, Tarantini L, Marinelli B, Bertazzi PA, Apostoli P, Beccarelli A. Effects of inhalable particulate matter on blood coagulation. *Journal of Thrombosis and Haemostasis* 2010; 8: 662-668
- 1285 Mannucci PM. Fine particulate: it matters. *Journal of Thrombosis and Haemostasis* 2010; 8: 659-661
- 1286 Peyvandi F, Palla R, Lotta LA, Mackie I, Scully MA, Machin SJ. ADAMTS-13 assays in thrombotic thrombocytopenic purpura. *Journal of Thrombosis and Haemostasis* 2010, 8: 631-640
- 1287 Mannucci PM. Genetic testing in von Willebrand disease: a rebuttal. *Journal of Thrombosis and Haemostasis* 2010; 8: 860 (letter)
- 1288 Baronciani L, Peyvandi F, Punzo M, Lancellotti S, Cianciani MT, Federici AB, De Cristofaro R. Relevance of chloride binding to von Willebrand factor in type 2B von Willebrand disease patients. *Journal of Thrombosis and Haemostasis* 2010; 8: 416-418
- 1289 Jedlitschky G, Cattaneo M, Lubenow LE, Rosskopf D, Lechi A, Artoni A, Motta G, Niessen J, Kroemer HK, Greinacher A. Role of MRP4 (ABCC4) in platelet adenine nucleotide-storage: evidence from patients with delta-storage pool deficiencies. *American Journal of Pathology* 2010; 176:1097-1103
- 1290 Mauri T, Bellani G, Patrignani N, Coppadoro A, Peri G, Cuccovillo I, Cugno M, Iapichino G, Gattinoni L, Pesenti A, Mantovani A. Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality. *Intensive Care Medicine* 2010; 36: 621-629
- 1291 Franchini M, Mannucci PM. Co-morbidities and quality of life in elderly persons with haemophilia. *British Journal of Haematology* 2010; 148: 522-533.
- 1292 Jespersen J, Poller L, Van den Besselaar AM, Van der Meer FJ, Palareti G, Tripodi A, Shiach C, Keown M, Ibrahim S. External quality assessment (EQA) for CoaguChek monitors. *Thrombosis and Haemostasis* 2010; 103: 936-941
- 1293 Giusti B, Saracini C, Bolli P, Magi A, Martinelli I, Peyvandi F, Raura M, Volpe M, Lotta LA, Rubattu S, Mannucci PM, Abbate R. Early-onset ischaemic stroke: analysis of 58 polymorphisms in 17 genes involved in methionine metabolism. *Thrombosis and Haemostasis* 2010; 103:1136-1144
- 1294 Cosmi B, Legnani C, Tosetto A, Pengo V, Ghirarduzzi A, Testa S, Prisco D, Poli D, Tripodi A, Palareti G; PROLONG Investigators; FCSA, Italian Federation of Anticoagulation Clinics. Comorbidities, alone and in combination with D-dimer, as risk factors for recurrence after a first episode of unprovoked venous thromboembolism in the extended follow-up of the PROLONG study. *Thrombosis and Haemostasis* 2010; 103: 1152-1160
- 1295 Cugno M, Ingegnoli F, Gualtierotti R, Fantini F. Potential effect of anti-tumor necrosis factor-alpha treatment on reducing the cardiovascular risk related to rheumatoid arthritis. *Current Vascular Pharmacology* 2010; 8: 285-292
- 1296 Cosmi B, Legnani C, Iorio A, Pengo V, Ghirarduzzi A, Testa S, Poli D, Tripodi A, Palareti G; PROLONG Investigators (on behalf of FCSA, Italian Federation of Anticoagulation Clinics). Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep vein thrombosis in the prolong study. *Haemophilia* 2010; 16:437-446.
- 1297 Cugno M, Tedeschi A, Asero R, Meroni PL, Marzano AV. Skin autoimmunity and blood coagulation. *Autoimmunity* 2010; 43: 189-194.
- 1298 Tagliaferri A, Rivolta GF, Iorio A, Oliovecchio E, Mancuso ME, Morfini M, Roncino A, Mazzucconi MG, Franchini M; Italian Association of Haemophilia Centers, Ciavarella N, Scoraggi A, Valdrè L, Tagariello G, Radossi P, Muleo G, Iannaccaro PG, Biasoli C, Vincenti D, Serino ML, Linari S, Molinari C, Boeri E, La Peccorella M, Carloni MT, Santagostino E, Di Minno G, Coppola A, Roncino A, Zanon E, Spiezio L, Di Perna C, Marchesini M, Marcucci M, Dragani A, Macchi S, Albertini P, D'Incà M, Santoro C, Biondo F, Pireddu G, Rossetti G, Barillari G, Gandini G, Giuffrida AC, Castaman G. Mortalità and causes of death in Italian persons with haemophilia, 1990-2007. *Haemophilia* 2010; 16:437-446.
- 1299 Mancuso ME, Berardinelli L. Arteriovenous fistula as stable venous access in children with severe haemophilia. *Haemophilia* 2010; 16 (Suppl 1): 25-28
- 1300 Santagostino E, Mancuso

ME. Venous access in haemophilic children : choice and management.  
**Haemophilia** 2010; 16 (Suppl 1) :20-24

1301 Bafunno V, Santacroce R, Chetta M, D'Andrea G, Pisanelli D, Sessa F, Trotta T, Tagariello G, Peyvandi F, Margaglione M. Polymorphisms in genes involved in autoimmune disease and the risk of FVIII inhibitor development in Italian patients with haemophilia A.  
**Haemophilia** 2010; 16 :469-473

1302 Santagostino E, Franchini M. Haemophilia: new challenges and winning directions.  
**Haemophilia** 2010; 16 (Suppl 1) : 1

1303 Saibeni S, Saladino V, Chantarangkul V, Villa F, Bruno S, Vecchi M, De Franchis R, Sei C, Tripodi A. Increased thrombin generation in inflammatory bowel diseases.  
**Thrombosis Research** 2010;125: 278-282

1304 Van den Besselaar AM, Chantarangkul V, Tripodi A. Effect of prothrombin time outlier exclusion rules on ISI calibration in multicentre studies.  
**Thrombosis Research** 2010;125: 523-528

1305 Tripodi A, Primignani M, Mannucci PM. Abnormalities of hemostasis and bleeding in chronic liver

disease : the paradigm's challenger.  
**Internal and Emergency Medicine** 2010; 5:7-12

1306 Capri S, Ageno W, Imberti D, Palareti G, Piovella F, Scannapieco G, Moia M. Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy : a cost-effectiveness analysis.  
**Internal and Emergency Medicine** 2010; 5 : 33-40

1307 Cugno M, Marzano AV, Asero R, Tedeschi A. Activation of blood coagulation in chronic urticaria: pathophysiological and clinical implications.  
**Internal and Emergency Medicine** 2010; 5:97-101

1308 Asero R, Tedeschi A, Cugno M. Heparin and Tranexamic Acid Therapy May Be Effective in Treatment-Resistant Chronic Urticaria with Elevated D-Dimer: A Pilot Study.  
**International Archives of Allergy and Immunology** 2010; 152 : 384-389

1309 Iapichino G, Umbrello M, Albicini M, Spanu P, Bellani G, Polli F, Pavlovic R, Cugno M, Fermo I, Paroni R. Time Course of endogenous nitric oxide inhibitors in severe sepsis in humans.  
**Minerva Anestesiologica** 2010; 76 : 325-333

1310 Tripodi A. The coagulopathy of chronic liver disease: is there a causal relationship with bleeding? No.  
**European Journal of Internal Medicine** 2010; 21 : 65-69

1311 Mannucci PM. Aspirin as antiplatelet agent in diabetes: Cons.  
**European Journal of Internal Medicine** 2010 ; 21: 154-156

1312 Cugno M, Castelli R, Bisiani G, Griffini S, Meroni PL. Anti-t-PA antibodies in acute myocardial infarction after thrombolysis with rt-PA.  
**European Journal of Internal Medicine** 2010; 21:25-9

Sono a disposizione le seguenti precedenti pubblicazioni:

**10 anni di attività (1976-1986)**

**Altri 5 anni di attività (1987-1991)**

**Verso i vent'anni di attività (1992-1994)**

**Più di vent'anni di attività (1995-1997)**

**Venticinque anni di attività (1998-2001)**

**Più di trent'anni di attività (2002-2005)**

che potranno essere fornite agli interessati, facendone richiesta alla Fondazione.

The reports 1976-1986, 1987-1991, 1992-1994, 1995-1997, 1998-2001 and 2002-2005 are available upon request from the Foundation.

**6x6 advertising  
Data Novembre 2010**

**FONDAZIONE ANGELO BIANCHI BONOMI**  
Piazza Castello 2  
20121 Milano - Italia  
Tel +39/2/86450532  
Fax +39/2/875444

e-mail:  
[fondazione.abb@gecami.it](mailto:fondazione.abb@gecami.it)  
[www.fondazionebianchibonomi.it](http://www.fondazionebianchibonomi.it)

**SEGRETERIA**  
Donatella Valeri  
[donatella.valeri@gecami.it](mailto:donatella.valeri@gecami.it)



## Fondazione Angelo Bianchi Bonomi

Piazza Castello, 2 - 20121 Milano Italy  
Tel. + 39 02 86450532 - fax + 39 02 875 444  
[www.fondazionebianchibonomi.it](http://www.fondazionebianchibonomi.it)

---